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Abstract 
 The cytochrome P450 (P450) superfamily of mixed function oxidase enzymes catalyze 
the metabolism of a variety of endogenous and exogenous biochemicals, including steroids, fatty 
acids, vitamins, eicosanoids, drugs, pesticides, and toxins. P450-mediated oxidative metabolism 
often serves a beneficial role in the clearance of foreign compounds and the regulation of 
endogenous molecules, both of which are necessary for the maintenance of homeostasis. 
However, the reactions catalyzed by P450 enzymes also have the potential to promote disease 
and injury, whether it be in the activation of procarcinogens or by undermining the therapeutic 
efficacy of a drug. Altogether, these processes make P450 enzymes important subjects of interest 
for the prediction of chemical toxicology and the development of therapeutic agents. The focus 
of this thesis research is the characterization of the CYP26 and CYP2A families of P450 
enzymes in an effort to contribute to an understanding of how substrates and inhibitors 
specifically interact with the individual enzymes within these families. 
 The functional enzymes of the human CYP2A family include CYP2A6 and CYP2A13. 
CYP2A6 is primarily a hepatic enzyme, while CYP2A13 is mainly expressed within the 
respiratory tract. Though these two enzymes are primarily localized to different tissues within the 
body, they share many substrates in common as a result of their 94% amino acid sequence 
identity. These substrates include: nicotine, cotinine, para-nitrophenol, and coumarin. However, 
CYP2A13 appears to preferentially activate a number of procarcinogens, including the tobacco-
specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), into reactive 
intermediates that can result in DNA adducts and the initiation or promotion of carcinogenesis. 
In order to evaluate the relative involvement of CYP2A6 activity versus that of CYP2A13 in the 
metabolism and/or activation of potentially harmful chemical agents in vivo, selective inhibitors 
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are needed. A number of compounds were reported to selectively inhibit CYP2A6 before 
CYP2A13 was determined to be a functional member of the CYP2A family, or have simply not 
been tested against CYP2A13. This work examined such compounds including: phenethyl 
isothiocyante (PEITC), 4-dimethylaminobenzaldehyde (DMABA), 8-methoxypsoralen (8-MOP), 
tranylcypromine, tryptamine, pilocarpine, (S)-nicotine, (R)-(+)-menthofuran, and β-nicotyrine. 
The relative impact of these inhibitors on CYP2A6 and CYP2A13 function was evaluated by 
determining Ki values and modes of inhibition for each of the compounds against both enzymes, 
followed by the calculation of a selectivity factor. The results of these studies serve as the first 
explicit determination of the selectivity of these compounds for enzymes within the CYP2A 
family and indicate that only (R)-(+)-menthofuran and tranylcypromine demonstrate even a 10-
fold preference for CYP2A6 inhibition over CYP2A13. This information can be used as a guide 
for the selection of inhibitors with the greatest potential for determining whether CYP2A6 or 
CYP2A13 is responsible for the metabolism or activation of procarcinogenic compounds, such 
as tobacco-derived NNK in the human respiratory tract. 
Collectively, the CYP26 family of P450 enzymes serve as important mediators of retinoic 
acid (RA) catabolism in the body. In humans, the CYP26 family of enzymes consists of three 
isoforms: CYP26A1, CYP26B1, and CYP26C1. As a result of RA’s endogenous role in 
regulating cellular growth and differentiation, geometric isomers of RA such as all-trans-RA 
(atRA) and 13-cis-RA represent attractive targets for cancer therapy and the treatment of 
dermatological conditions. Unfortunately, RA resistance is often experienced in patients 
undergoing prolonged RA-based therapy. This failure has been suggested to be the result of up-
regulation of P450 enzymes, particularly the enzymes of the CYP26 family, resulting in 
enhanced RA metabolism in vivo. As a result, a significant amount of work has been conducted 
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for the development of chemical agents that inhibit P450-mediated metabolism of atRA, 
commonly referred to as retinoic acid metabolism blocking agents (RAMBAs). The development 
of safe and effective RAMBAs could be greatly facilitated by more detailed structural and 
functional characterizations of the CYP26 family of enzymes, since very little is known about 
these enzymes aside from their dominant role in atRA hydroxylation. However, the fact that the 
human CYP26 enzymes are membrane-bound proteins, a characteristic shared by all human 
P450 enzymes, represents a major challenge to the recombinant expression and purification of 
these enzymes in sufficient quantities to enable detailed biochemical and biophysical 
characterization studies. To address this challenge, a new method for the production of pure 
CYP26 enzymes was developed based on techniques that have proven successful in the 
expression and purification of other membrane-bound P450 enzymes in E. coli, while 
incorporating the use of detergents and stabilizing ligands specific to the CYP26 enzymes. The 
combination of these approaches led to the successful generation of mouse CYP26A1 and 
CYP26B1 proteins in yields of 200-400 nmol per 2.25 L of E. coli expression media and the 
ability to recover 20-50 nmol following a single chromatographic step. Unfortunately, this 
protein appeared to be inactive according to reduced carbon monoxide difference spectrum 
analysis and assays of RA metabolism. As a result, further optimization will be required to reach 
the original goal set forth to generate pure recombinant CYP26 enzymes for basic kinetic and 
structural determination studies. 
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Chapter 1 
Introduction 
Introduction to Cytochrome P450 Enzymes 
Cytochrome P450 (P450) enzymes are a superfamily of heme-containing proteins that 
catalyze mixed-function oxidation reactions and are found within a variety of organisms, 
including plants, microorganisms, and mammals. The function of P450 enzymes in early forms 
of life is considered to have primarily involved the regulation of endogenous molecules, such as 
the metabolism of cholesterol to maintain membrane integrity and for steroid biosynthesis and 
metabolism.1 In pharmacology, P450 enzymes are often better known for their metabolism of 
foreign compounds (xenobiotics). This capacity is believed to have evolved from the role of 
steroidogenic P450 enzymes in protecting organisms from plant toxins,1 which expanded today 
to protection from man-made chemical exposures in the form of drugs, common household 
products, pollutants, and industrial waste. As a result, P450 enzymes have evolved to metabolize 
a wide variety of substrates from diverse structural classes, while maintaining an overall 
conserved tertiary structure that is uniquely adapted to the heme-thiolate chemistry required for 
oxygen activation. 
 P450 enzymes are classified by an alphanumerical naming system based on evolutionary 
relationships.2 The name of each enzyme begins with the abbreviation ‘CYP’ to signify its 
membership within the cytochrome P450 superfamily. P450 enzymes are further categorized into 
families and subfamilies according to amino acid sequence homology. Enzymes of the same 
family share a minimum of 40% sequence identity and are distinguished by the first number 
following the ‘CYP’ abbreviation (i.e. CYP2). The letter following the family number is shared 
by members of the same subfamily, requiring an amino acid identity of >55% (i.e. CYP2A). The 
2 
 
final number is given to an individual enzyme originating from a single gene (i.e. CYP2A6). As 
a result, enzymes having highly conserved evolutionary relationships can be readily identified 
based on the similarity of their names. 
In humans, the P450 enzymes represent 18 families and 43 subfamilies.3 Of the 57 human 
P450 enzymes identified to date, 42 have been classified according to the substrate class in 
which they demonstrate catalytic activity (Table 1-1).4 P450 enzymes from families 1-3 are 
primarily involved in the metabolism of xenobiotics and are generally characterized as having 
broad, overlapping substrate specificities.5 The levels of these P450 enzymes can vary 
considerably among individuals and are often highly inducible by chemical exposures, leading to 
large differences in the ability to metabolize many drugs.6 Families 4 and higher, by contrast, 
primarily participate in the metabolism of compounds endogenously found in humans and 
selectively metabolize a limited number of substrates.5 The levels of these P450 enzymes are 
both relatively consistent among individuals and more tightly regulated, and deficiencies in their 
expression or catalytic activities can lead to serious human diseases.7 
Features of Cytochrome P450 Enzymes 
Human P450 enzymes are all membrane-bound proteins, the majority of which are 
localized to the endoplasmic reticulum (ER) of the cell.7 The membrane-bound nature of these 
proteins is thought to reflect the hydrophobic properties of their substrates. Hydrophobic 
substrates that tend to be concentrated within the membranes are thought to access the P450 
active site via the membrane-bound face of the enzyme. Two separate hydrophobic regions are 
responsible for the close association of human P450 enzymes with the membrane. The first is an 
N-terminal transmembrane helix consisting of approximately 20 hydrophobic amino acids 
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inserted co-translationally into the membrane. The second hydrophobic region is one face of the 
protein surface proximal to the active site. Together, these two regions represent a significant 
challenge to the study of human P450 enzymes, as they confer properties that make these 
proteins particularly challenging to extract from the membrane and to solubilize for purposes of 
purification and biophysical and biochemical characterization. As a result, almost all of the 
published crystal structures and many characterizations of highly purified human P450 enzymes 
are of enzymes from which the N-terminal transmembrane domain has been removed. This 
truncation not only improves solubility due to the removal of one region that anchors the protein 
to the membrane, but is also beneficial due to increased expression levels in E. coli without 
altering the catalytic activity of the enzyme.8 
The catalytic domain of human P450 enzymes is located on the cytoplasmic side of the 
ER membrane, and contains an iron protoporphyrin IV (commonly referred to as the heme) 
Xenobiotics Steroids Fatty Acids Vitamins Eicosanoids Unknown 
1A1 2C19 1B1 19A1 2J2 2R1 4F2 2A7 4V2 
1A2 2D6 7A1 21A2 4A11 26A1 4F3 2S1 4X1 
2A6 2E1 7B1 27A1 4B1 26B1 4F8 2U1 4Z1 
2A13 2F1 8B1 39A1 4F12 26C1 5A1 2W1 20A1 
2B6 3A4 11A1 46A1  27B1 8A1 3A43 27C1 
2C8 3A5 11B1 51A1  24A1  4A22  
2C9 3A7 11B2     4F11  
2C18  17A1     4F22  
Table 1-1. Human P450 enzymes categorized by substrate class.4 
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prosthetic group (Figure 1.1 A) that is crucial to their function as monooxygenase enzymes. The 
iron of the heme is coordinated to a phylogenetically-conserved cysteine thiolate. When the sixth 
coordination position of the reduced heme iron is occupied by carbon monoxide (Figure 1.1 A), 
the result is a difference spectrum with a maximum at 450 nm (Figure 1.1 B). This characteristic 
spectrum differs from heme proteins where the heme iron is coordinated to histidine or tyrosine, 
and thus serves as the origin of the name ‘cytochrome P450’. The reduced carbon monoxide 
difference spectrum of P450 enzymes is widely used to determine the concentration of active 
P450 in an enzyme preparation. Perturbations of the bond between the heme iron and the 
cysteinyl sulphur result in an altered electronic structure upon complexing with carbon 
monoxide, which corresponds to an observed absorption maximum at 420 nm rather than 450 
nm. Although in rare instances P420 has been shown to convert to P450, absorption at 420 nm is 
usually considered to be an indicator of the irreversible formation of inactive P450 enzyme.  
 
N
Fe
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H3CH3C
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O
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Figure 1.1. Ferrous heme thiolate catalytic center of cytochrome P450. The iron 
protoporphyrin within the P450 catalytic domain is coordinated to the sulfur of cysteine (A) and 
has the ability to form a complex with carbon monoxide, yielding a major absorption band at 450 
nm (B) in the reduced carbon monoxide difference spectrum. 
A B 
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Cytochrome P450 Catalytic Cycle 
The primary function of P450 enzymes as monooxygenases is to introduce an oxygen 
atom into a usually stable, hydrophobic compound. This is typically accomplished through 
activation of molecular oxygen and reduction the distal oxygen atom to water followed by 
incorporation of the remaining oxygen atom into the organic substrate (Figure 1.2). Oxidative 
metabolism by P450 enzymes results in one or more of the following changes to the molecules 
that serve as P450 substrates, including: 1) increased hydrophilicity, 2) reduced chemical 
stability, or 3) generation of a functional group, facilitating subsequent conjugation to a more 
polar molecule. For the majority of 
P450 substrates, the result is metabolic 
deactivation and elimination from the 
body. Some substrates, however, 
become metabolically activated by the 
very same mechanism, either to a 
biologically active therapeutic molecule (prodrug) or to a more harmful chemical species 
(protoxins, procarcinogens). An example of metabolic activation by P450 enzymes will be 
discussed later in this chapter in the case of the procarcinogenic tobacco-specific nitrosamine 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and the closely-related xenobiotic-
metabolizing enzymes CYP2A6 and CYP2A13. 
 Oxidative metabolism by CYP450 enzymes is accomplished through a catalytic cycle9 
(Figure 1.3) that requires the delivery of two electrons and two protons for every substrate that is 
oxidized. The electrons are derived from NADPH or NADH and transported to the P450 heme 
iron via one or more redox partner proteins. For human P450 enzymes localized within the ER,  
Figure 1.2. Cytochrome P450-catalyzed 
monooxygenase reaction. The cytochrome P450-
mediated reaction involves the combination of 
oxygen with organic substrate (RH) to produce a 
molecule of water and a monooxygenated metabolite 
(ROH). 
RH+O2  
2H+,    2e-­‐
!⎯⎯⎯⎯! ROH+H2O 
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Figure 1.3. The cytochrome P450 catalytic cycle. 9 
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this redox partner is NADPH-dependent cytochrome P450 reductase (CPR). CPR is a 
flavoprotein complex that consists of one FAD (flavin adenine dinucleotide) and one FMN 
(flavin mononucleotide) per CPR protein. CPR facilitates the transfer of electrons from NADPH 
to FAD to FMN and finally to P450 for completion of the catalytic cycle. As P450 enzymes are 
continuously turning over substrates, a constant flow of electrons is necessary to maintain P450-
mediated oxidative metabolism. 
In the resting state of the P450 enzyme (1), a distal iron-coordinated water molecule 
occupies the sixth coordination site on the ferric heme iron. The P450 catalytic cycle begins with 
the reversible binding and orientation of a substrate within the enzyme’s active site, which 
typically displaces the water molecule present during the resting state (2). The transition from a 
six-coordination state to a five-coordination state means the heme iron converts from low-spin to 
high-spin, raising the reductive potential from approximately -300 mV to -170 mV and 
effectively making the complex a good electron acceptor for CPR. This triggers a one electron 
transfer from the FMN of CPR, reducing the heme iron from high-spin ferric to high-spin ferrous 
(3). The reduced heme iron readily binds dioxygen as the sixth ligand (4). At this point, the P450 
enzyme accepts a second electron from CPR to form a twice-reduced ferric-peroxy species (5), 
which becomes protonated in the following step to produce a ferric hydroperoxy species (6). A 
second protonation at the distal oxygen atom and subsequent cleavage of the O-O bond produces 
a water molecule and a ferryl-oxo intermediate (7). This intermediate, sometime referred to as 
“Compound I”, represents the catalytically active oxygenation species responsible for activating 
the substrate. Activation proceeds by abstraction of a hydrogen atom from the substrate, and 
subsequent rebound generates the oxidized product. The cycle ends with dissociation of the 
product and the re-binding of water to the ferric heme iron (1). 
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The P450 catalytic cycle contains three branch points where it is possible to prematurely 
abort the reaction, commonly referred to as ‘shunt’ pathways. The autooxidation shunt involves 
the autooxidation of the oxy-ferrous enzyme (4) with the concomitant production of a superoxide 
anion and return of the enzyme to the substrate-bound state (2). The peroxide shunt occurs when 
the coordinated peroxide (6) dissociates from the iron and forms a hydrogen peroxide to return 
the enzyme to the substrate-bound state (2). The final uncoupling pathway is the oxidase shunt, 
in which the ferryl-oxo intermediate (7) is reduced to water by two additional electrons and is 
returned to the substrate-bound state (2) rather than proceeding to substrate oxidation through 
hydrogen abstraction. 
Relevance of Cytochrome P450 Enzymes in Xenobiotic Metabolism 
Of all the enzyme systems present in the human body, P450 enzymes are the most 
important in terms of drug metabolism. Three quarters of all drug metabolism is mediated by 
P450 enzymes, and 95% of all drugs are metabolized by just five of the fifteen human P450 
enzymes devoted to the metabolism of xenobiotics.6 As a result, a significant amount of 
consideration is given to the activity of these enzymes in drug development. 
The development of a successful drug candidate critically depends on four main criteria: 
absorption, distribution, metabolism, and excretion (ADME).10 These four criteria influence the 
levels of exposure of a drug within the body, and therefore the drug’s pharmacological activity 
and overall effectiveness as a therapeutic agent. P450 enzymes have a major impact on the 
ADME properties of a drug based on the dominant role they play in xenobiotic metabolism. As a 
result, the Federal Drug Administration (FDA) requires specific information concerning the 
ability of a new chemical entity to inhibit, induce, or serve as a substrate to one or more P450 
enzymes.6 This information is critical to reducing the occurrence of severe clinically-significant 
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drug interactions as a result of toxicity, understanding pharmacological effectiveness, and 
evaluating potential drug-drug interactions. 
P450 reaction phenotyping studies serve as a primary means of assessing the contribution 
of individual P450 enzymes to the metabolism of a drug candidate. Multiple in vitro approaches 
have been developed for this purpose, including: the incubation of human liver microsomes in 
the presence of various inhibitors, the use of recombinant enzyme isoforms, and correlation 
studies in human liver microsomes to compare the metabolism of a new compound to that of a 
probe substrate.11 The first of these three approaches is perhaps the most effective and widely 
used, and depends heavily on the use of inhibitors that are both potent and selective for each of 
the P450 enzymes present in the microsomes. Since many xenobiotic-metabolizing P450 
enzymes can bind and metabolize a wide variety of substrates, it can be difficult to identify 
compounds that can provide maximal inhibition of one P450 while marginally affecting other 
isoforms at a given concentration. Nevertheless, broad efforts to this end have successfully 
identified selective inhibitors for many of the major human hepatic P450 enzymes.11 
In addition to their utility in evaluating drug metabolism, selective inhibitors are also 
fundamental in determining the relative roles that individual P450 enzymes have in the 
metabolism of potentially harmful compounds to which we are exposed in our daily lives. 
Fortunately, these same P450 enzymes actively metabolize compounds that we encounter in the 
air we breathe and in the food we eat. While the liver plays a dominant role in the first-pass 
clearance of drugs and controls their systemic levels, extrahepatic tissues that serve as portals of 
entry into the body provide very different settings for the metabolism of potentially harmful 
foreign compounds. Based on the nature of P450-mediated oxidative metabolism, the activity of 
these enzymes influences the level of localized tissue exposure to foreign compounds not only by 
10 
 
detoxifying harmful compounds, but also sometimes by activating inert xenobiotics to form toxic 
or carcinogenic compounds.12 Though the former is a beneficial process that proceeds relatively 
unnoticed, the threat imposed by the latter provides an opportunity to exploit the metabolic 
activity of individual P450 enzymes for purposes of cancer prevention. 
The Role of Human Cytochrome P450 2A Enzymes in the Metabolic Activation of 
Procarcinogens and the Significance of Selective Inhibitors 
 
The first project that will be discussed within this thesis is directly related to evaluating 
the roles of xenobiotic P450 enzymes that activate procarcinogenesis in extrahepatic tissues. 
Two closely related xenobiotic-metabolizing P450 enzymes, CYP2A6 and CYP2A13, represent 
the only two functional enzymes within the human CYP2A subfamily and share an amino acid 
sequence identity of 94%.13 CYP2A6 is primarily a hepatic enzyme, while CYP2A13 is mainly 
expressed within the respiratory tract.14 The CYP2A enzymes both metabolize many small, 
cyclic compounds, including nicotine,15 para-nitrophenol,16 coumarin,14 and the nicotine-derived 
compound cotinine.15 In addition, there are many other procarcinogenic compounds that 
CYP2A13 preferentially metabolizes or has the sole ability to activate. CYP2A13 is much more 
efficient in the metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone (NNK)14 compared to CYP2A6, and has the sole ability to metabolize the 
tobacco-related procarcinogen 4-aminobiphenyl17 and activate the mycotoxin aflatoxin B118 to 
carcinogenic/toxic epoxide metabolites. Of the potentially harmful xenobiotic compounds that 
CYP2A13 metabolizes, the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) continues to cause the greatest concern. 
Tobacco use is considered to be the most widespread link between exposure to known 
carcinogens and death from cancer.19 Cigarette smoking alone accounts for 90% of lung cancer 
cases worldwide, although all tobacco products, whether burned or unburned, contain a diverse 
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array of chemicals that lead to the development of 
various types of cancers.19 Cigarette smoke contains 
more than 60 compounds demonstrating 
carcinogenic potential, while unburned tobacco 
products contain more than 16.19 Among these 
compounds are nitrosamines such as NNK, Nʹ′–
nitrosonornicotine (NNN), and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL), which are formed from nicotine during the 
processing of tobacco and tobacco smoking 
(Figure 1.4).20 Of these, NNK is the most prevalent 
and considered by experts to represent one of the 
largest contributing factors to the formation of human tobacco-related lung cancer.19  
NNK is metabolically activated by P450 enzymes to form DNA adducts in lung tissue 
that can cause cancer. CYP2A6 and CYP2A13 are both able to perform this metabolic activation 
of NNK, though they do so at very different rates and at different sites. Activation of NNK 
proceeds through α-hydroxylation of either the methyl or methylene carbon, which generates 
electrophiles that pyridyloxobutylate or methylate DNA, respectively (Figure 1.5).21 CYP2A6 
has only been shown to catalyze the α-hydroxylation of the methyl carbon, while CYP2A13 
catalyzes the α-hydroxylation of the methyl carbon with much greater catalytic efficiency, in 
addition to catalyzing α-hydroxylation of the methylene carbon.14 The greater efficiency of 
CYP2A13 for NNK activation, coupled with the fact that CYP2A13 is primarily expressed in the 
Figure 1.4. The procarcinognic 
nitrosamines NNN, NNK, NNAL, and 
the tobacco alkaloid precursor 
nicotine.21 
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respiratory tract where inhaled nitrosamines are most concentrated, makes CYP2A13 a leading 
target for the prevention of lung cancer as a result of NNK exposure. 
Other members of the Scott lab have focused on addressing the immediate, therapeutic 
need to selectively inhibit CYP2A13 activity in the activation of NNK in the respiratory tract. 
However, the contribution that CYP2A6 and CYP2A13 have in the metabolism and activation of 
xenobiotic compounds, in addition to NNK, represents a general need for chemical tools that can 
be used to determine isozyme-specific metabolic contributions within a given tissue. As a result, 
Figure 1.5. NNK α-hydroxylation and formation of DNA adducts. The pyridyl and methyl 
adduct precursors are colored blue and red, respectively.21 
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the focus of my project was to evaluate the ability of known CYP2A inhibitors to discriminate 
between the activity of CYP2A6 and CYP2A13. The data attained from these studies can be used 
as a guide for the selection of CYP2A-selective inhibitors for CYP phenotyping studies, while 
contributing to a greater understanding of the biochemical basis for selective interactions 
between CYP2A enzymes and their ligands. 
The Cytochrome P450 26 Family of Enzymes, Retinoic Acid Metabolism, and Relevance to 
Cancer Therapy 
 
Whereas the CYP2A family of enzymes represent therapeutic targets for the prevention 
of cancer due to their roles in the metabolic activation of xenobiotics, inhibition of the next 
family of cytochrome P450 enzymes provides a means for enhancing existing cancer therapies 
by regulating the concentrations of retinoic acid (RA), the endogenous derivative of vitamin A 
(retinol) (Figure 1.6). In humans, the CYP26 family of enzymes consists of three isoforms 
responsible for the metabolism of RA and its structural isomers (collectively referred to as RAs): 
CYP26A1, CYP26B1, and CYP26C1. In contrast to the xenobiotic-metabolizing enzymes of the 
CYP2A subfamily, the singular role of the CYP26 family of enzymes is to mediate the levels of 
endogenous RAs. Consequently, the CYP26 enzymes recognize only this small group of 
compounds as their substrates. RA plays a major role in regulating growth and differentiation of 
a wide variety of cell types, and this is involved in several important physiological processes, 
including reproduction, cell proliferation, differentiation, vision, and embryonic development.22 
At the cellular and tissue levels, the need for tight regulation of RA concentrations is well 
demonstrated by the observations that both deficiency and excess of RA are teratogenic to the 
embryo during critical developmental periods.23 This tightly regulated concentration of RA 
within the body is maintained by both the synthesis of RA from vitamin A and by its 
metabolism, with the physiologically most prominent pathway being oxidative metabolism of 
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atRA to 4-OH-RA. Though several P450 enzymes have been documented for their ability to 
metabolize RA, the enzymes CYP26A1 and CYP26B1 appear to be the most dedicated to the 
oxidative metabolism of atRA to 4-OH-RA, in addition to being atRA-inducible.24-26 
Figure 1.6. The synthesis of retinoic acid from retinol and metabolism by CYP26 enzymes. 
Retinol (vitamin A) is oxidized to all-trans-retinaldehyde by retinol dehydrogenase, which is 
subsequently oxidized by retinaldehyde dehydrogenase to retinoic acid. Retinoic acid can 
chemically exist as several different geometric isomers, including 13-cis-retinoic acid, 9-cis-
retinoic acid, and all-trans-retinoic acid. All-trans-retinoic acid represents the biologically most 
active metabolite of vitamin A and is metabolized to 4-hydroxy-all-trans-retinoic acid by 
CYP26 enzymes.  
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 Pharmacological doses of RAs are useful in the treatment of some types of cancers and 
dermatological conditions by restoring normal differentiation responses within abnormal cells. 
All-trans-RA (atRA or tretinoin) is approved to induce cytodifferentiation and decrease 
proliferation of acute promyelocytic leukemia, while the RA isomer 13-cis-RA (isotretinoin) is 
used for treatment of severe acne that has been unresponsive to other forms of treatment. 
Unfortunately, RA resistance is often experienced in patients undergoing prolonged RA-based 
therapy. Part of this resistance is due to increased plasma clearance of atRA, for which P450 
enzymes such as the CYP26s are known to play a dominant role. Therefore, an emerging 
strategy in the field of cancer chemoprevention and treatment is preventing in vivo metabolism of 
atRA through inhibition of CYP26 enzymes. P450 inhibitors designed for this purpose are 
referred to as retinoic acid metabolism blocking agents (RAMBAs).  
Liarozole (1; Figure 1.7) is the most studied RAMBA and the first RAMBA to be 
approved for clinical use. It was originally identified as a modest inhibitor of atRA 
hydroxylation in vitro (IC50=2.2-6.0 µM) by researchers at Janssen Research Foundation.27 As a 
result, it was developed clinically for the treatment of both metastatic prostate cancer and ER-
negative metastatic breast cancer, and has additionally been extensively investigated as a 
potential agent for the treatment of dermatological diseases such as psoriasis and ichthyosis.27 Its 
development for the treatment of cancer, however, was eventually discontinued due to its lack of 
P450 enzyme specificity and the fact that it only demonstrates moderate potency as an atRA 4-
hydroxylase inhibitor.28  
Since liarozole’s failure in the clinic, significant efforts have been made to obtain 
RAMBAs that demonstrate enhanced specificity. These efforts have resulted in the development 
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Figure 1.7. Retinoic acid metabolism blocking agents designed for the inhibition of 
CYP26. Structures of Liarazole (1), R115866 (2), R116010 (3), and naphthalene lead 
compounds identified by researchers at OSI Pharmaceuticals Inc. (4) and University of Cardiff 
(5). 
of several compounds that demonstrate potent, nanomolar inhibition of atRA hydroxylation vitro 
with greater selectivity towards atRA metabolizing enzymes than liarozole.Examples 
include the highly potent second generation benzothiazole inhibitors R115866 and R116010 
developed by researchers at Johnson and Johnson Pharmaceuticals (previously Janssen Research 
Foundation). R115866 (2; Figure 1.7) is reported to be highly selective for CYP26 and to 
potently inhibit CYP26A1 with an IC50 of 4 nM, which is nearly 1000-fold more potently than 
liarozole.29 R116011 (3; Figure 1.7) is a dimethylamino derivative of R115866 and is reported to 
potently inhibit atRA metabolism catalyzed by CYP26A1 with an IC50 of 8.7 nM while 
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maintaining selectivity against human P450 enzymes CYP19, CYP2C11, CYP2A1, CYP3A, and
CYPB1/2.30  
The 2,6-disubstituted napthalenes are one of the newest classes of novel RAMBAs and 
are based on the fusion of the imidazolyl propylamino moiety of R116010 with a naphthalene 
core with a substitution at the 6-position. This class of compounds was first introduced by 
researchers at OSI Pharmaceuticals, whose lead compound (4) demonstrated an IC50 of 20 nM 
against CYP26A1-mediated atRA metabolism and favorable selectivity for CYP26 over 
CYP3A4, CYP1A2, CYP2D6, and CYP2C9.31 The most recent naphthyl-based RAMBAS to be 
reported come from a series of 3-(1H-imidazol- and triazol-1-yl) -2,2-dimethyl-3-[4-(napthalen-
2-ylamino)phenyl]propyl derivatives developed by researchers at the University of Cardiff, 
UK.32 All of these latter derivatives that were tested demonstrated inhibition of CYP26A1 equal 
to or better than R116010. The leading compound, a triazole ester derivative (5), demonstrated 
nearly 30-fold increased potency (IC50=0.35 nM) compared to R116010, while retaining almost 
identical P450 selectivity against P450 enzymes CYP1A2, CYP2C9, CYP2C19, and CYP2D6.32  
It remains to be seen how the results of the in vitro studies of the various 2,6-
disubstituted napthalene inhibitors translate in vivo and to what extent R116010 and R115866 
will be developed in the clinic, but the high inhibitory potencies and selectivity for CYP26A1 
suggest that they will be less likely to produce the unwanted side effects experienced with 
lizarozole therapy. However, to facilitate the development of truly selective CYP26 inhibitors 
and improved RAMBAs, more detailed structural and functional characterization of the CYP26 
family of enzymes is needed. Aside from their dominant role as atRA-hydroxylases, very little is 
known about their structures, metabolic pathways, or kinetics. Present limitations in CYP26 
research are due, in large part, to that fact that like all P450 enzymes, CYP26 enzymes are 
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membrane-bound proteins, which makes them both difficult to express recombinantly and to 
purify. As a result, the majority of CYP26 research conducted to date has relied on assays 
conducted with transfected cells or microsomal fractions prepared from tissue samples or 
cultured cells.25,32-35 These studies provide only limited structural and functional data based on 
the scarce quantities and low purity of these types of enzyme preparations. As a result, the 
immediate goal of this second project was the production of recombinant CYP26 enzyme that 
exceeded the yield and purity attainable by previous methods. 
Our approach to building a new method for the production of pure CYP26 enzymes was 
to apply techniques that have proven successful in the expression and purification of other 
membrane-bound P450 enzymes in E. coli, including the use of detergents and stabilizing 
ligands specific to the CYP26 enzymes. In following with literature precedence for the other 
mammalian P450 enzymes, the amino acid sequences of the CYP26 enzymes were modified to 
facilitate recombinant expression in E. coli and purification by metal affinity chromatography. 
The detergents sodium cholate and Tergitol NP-10 were used based on their demonstrated utility 
in the purification of CYP26 enzymes expressed recombinantly in insect cells.24,36 Further efforts 
to optimize CYP26 expression and purification incorporated the use of the endogenous substrate 
RA, the clinically developed RAMBA liarozole, and representative compounds within the 3-
(1H-imidazol- and triazol- 1-yl)-2,2-dimethyl-3-[4-(napthalen-2-ylamino)phenyl]propyl series of 
inhibitors to facilitate protein stability by occupying the protein’s active site. Together, the 
application of proven methods for the expression and purification of other mammalian truncated 
P450 enzymes with the use of detergents and stabilizing ligands specific for the CYP26 enzymes 
provided a rational approach for generating significant amounts of pure protein. It was 
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envisioned that development of such a protocol would enable basic structural and kinetic studies 
to facilitate the development of enhanced RAMBAs for the treatment of cancer. 
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Chapter 2 
Methods 
Introduction 
 The studies summarized within Chapters 3 and 4 have several methods in common. For 
the most part, these methods consist of common biochemical research techniques or have been 
generated based on established protocols within the cytochrome P450 field. Modifications to 
these protocols were made according to the enzymes that served as the subjects of these studies 
and the instrumentation available within the lab. As a result, the methods described within this 
chapter are applicable to studies of the CYP2A subfamily proteins (Chapter 3) as well as the 
CYP26 family of proteins (Chapter 4). Methods specific to a single project, in contrast, can be 
found in the individual project chapters. This includes, but is not limited to, the engineering of 
plasmid DNA of individual P450 enzymes, optimization of a protocol for the expression and 
purification of the CYP26 proteins, as well as assays characterizing metabolism by CYP26 
enzymes or inhibition of CYP2A enzymes. 
Plasmid Transformation and Expression of Cytochrome P450 Proteins in E. coli 
Transformation 
The pKK233-3 plasmids containing the respective modified P450 genes (for CYP2A 
proteins see references (1,2); for CYP26 proteins see Chapter 4) were transformed into E. coli 
tetracycline-resistant TOPP-3 cells (Stratagene, La Jolla, CA) using the following procedure. To 
begin, E. coli TOPP-3 chemically competent cells (50 µL) were incubated on ice for 40 minutes 
with 0.5 µL pKKP450 plasmid, followed by heat shock at 42 °C for 30 seconds to facilitate 
uptake of the DNA. Next, super optimal catabolite repressive (SOC) media (1 mL) containing 
1.7 µL of 10% β-mercaptoethanol (BME) was added to the cells, which were then incubated at 
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37 °C for an hour with shaking at 250 rpm. Following this recovery period, brief centrifugation 
at 10,000 x g was used to pellet the cells, and all but ~100 µL of supernatant was removed. In the 
final step, the pelleted cells were resuspended in the remaining supernatant and spread on 
Lysogeny Broth (LB) plates containing 50 µg/mL ampicillin. Plates were incubated overnight at 
37 °C to grow isolated colonies.  
Expression 
Cytochrome P450 proteins were expressed recombinantly in E. coli TOPP-3 cells based 
on procedures described by others.1-3 To begin, a single colony selected from the overnight plate 
was used to inoculate 5 mL of LB media containing 50 µg/mL ampicillin and 25 µg/mL 
tetracycline. This culture was incubated at 37 °C with shaking at 250 rpm for approximately 8 
hours. Two larger cultures of LB media were then grown by inoculating 50 µL of the 5 mL 
culture into 200 mL LB media containing 50 µg/mL ampicillin and 12.5 µg/mL tetracycline. 
These 200 mL starter cultures were grown at 37 °C with shaking at 250 rpm overnight. The final 
scale-up was accomplished by introducing 15 mL of the 200 mL overnight starter cultures into 
each of 18 1L-flasks containing 225 mL of Terrific Broth (TB) media, 25 mL of TB salts, and 50 
µg/mL ampicillin. These expression cultures were grown for approximately 2 hours at 37 °C 
with shaking at 250 rpm until an OD600 of 1.0-1.5 was reached. Cytochrome P450 expression 
was initiated at that point by adding 240 µg/mL isopropyl β-D-1-thiogalactopyranoside, and 
heme generation was facilitated with the addition of 80 µg/mL δ-aminolevulinic acid (ALA). 
These expression cultures were incubated for a total of three days at a reduced temperature of 30 
°C with shaking at 190 rpm. Following the third day of expression, the cells were harvested by 
centrifugation at 6,500 x g for 10 minutes. The cell pellets were collected into 50 mL conical 
tubes and stored at -80 °C until purification. 
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Cytochrome P450 Protein Purification 
CYP2A6 and CYP2A13 were purified using a standard protocol developed and 
optimized previously.1,3 Each of the CYP26 proteins of interest were initially purified using the 
same protocol used for the purification of CYP2A proteins. This standard protocol was further 
optimized for the purification of the CYP26 proteins to maximize protein yield. The standard 
purification protocol is described in detail below, whereas the optimization to the standard 
protocol for the CYP26 proteins can be found in the methods section of Chapter 4: Expression 
and Purification of the Cytochrome P450 26 Family of Enzymes. 
 The isolation of membrane-associated P450 protein was accomplished by a combination 
of approaches including: enzymatic lysis, flash freezing, homogenization, sonication, detergent 
solubilization, and centrifugation.4 To begin with, the frozen cell pellet was thawed and 
resuspended in 200 mL of 20 mM potassium phosphate, pH 7.4, containing 20% glycerol. 
Spheroplasts were then produced by treating the suspension for 30 min with 0.3 mg/mL 
lysozyme with stirring at 4 °C and adding an equal volume of cold water to the stirring mixture. 
After stirring at 4 °C for 10 min, these spheroplasts were pelleted by centrifugation at 10,000 x g 
for 15 min at 4 °C. The spheroplasts were then lysed by freezing the pellets in situ using either a 
liquid nitrogen bath or a dry ice/ethanol slurry. The frozen pellets were thawed, suspended in 100 
mL of 500 mM potassium phosphate, pH 7.4, containing 20% glycerol, and homogenized by 
hand. The resulting suspension was sonicated using three 30 sec pulses with 60 sec of cooling on 
ice between pulses. The material was then centrifuged at 10,000 x g for 15 min at 4 °C, and the 
protein within the resulting supernatant fraction was solubilized by treatment with a detergent 
with stirring at 4 °C for 30 minutes. For the CYP2A proteins, the detergent employed was 
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Cymal-5 at a concentration of 4.8 mM (twice the critical micellar concentration). Optimization 
of the standard protocol for CYP26 proteins involved the use of 1% each of Tergitol (type NP-
10) and sodium cholate. The solution was then centrifuged at 100,000 x g for 60 min at 4 °C to 
separate the solubilized P450 protein from the membrane lipids. 
Following successful isolation from the membrane, P450 protein was purified using 
successive chromatographic steps on an ÄKTApurifier 10 FPLC system (GE HealthCare, Umeå, 
Sweden) by means of immobilized metal affinity chromatography and cation exchange 
chromatography. While both chromatographic steps were applied to the purification of CYP2A 
proteins used in kinetic studies, it should be noted that CYP26 protein was rarely recovered from 
the NiNTA column in high enough yield to allow for a second chromatographic step. The first 
column in the purification scheme was a nickel nitrilotriacetic acid (NiNTA) immobilized metal 
affinity column (Qiagen, Valencia, CA), since the 4X-histidine tag engineered onto the C-
terminus of the P450 enzymes has a highly selective interaction with Ni2+. This interaction 
allows for rapid and effective isolation of His-tagged P450 protein from most other proteins. The 
solubilized P450-containing solution was loaded onto a NiNTA column that had been 
equilibrated with loading buffer (100 mM potassium phosphate, pH 7.4, 20% glycerol, 0.2 M 
NaCl, 4.8 mM Cymal-5). Non-specifically bound fractions were removed from the column by a 
two-column volume wash of loading buffer. Impurities with a weak affinity for the NiNTA 
column were removed by an 8 mM histidine wash buffer (100 mM potassium phosphate, pH 7.4, 
20% glycerol, 0.2 M NaCl, 4.8 mM Cymal-5, 8 mM histidine), although the wash buffer at this 
step was substituted with loading buffer for the purification of CYP26 proteins. His-tagged P450 
protein was eluted from the NiNTA column with an 80 mM histidine elution buffer (10 mM 
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potassium phosphate, pH 7.4, 20% glycerol, 0.1 M NaCl, 4.8 mM Cymal-5, 80 mM histidine, 2 
mM EDTA).  
The carboxymethyl (CM) sepharose cation exchange column (GE HealthCare, Umeå, 
Sweden) employed in the next step served to further purify the P450 proteins based on charge-
charge interactions. Given a buffer pH of 7.4 and an isoelectric point (pI) of ~9 for CYP26 and 
CYP2A proteins, the negatively charged resin of the CM column binds efficiently to the overall 
positively charged P450 proteins. Fractions containing the most P450 (as evaluated by 
absorbance at 418 nm) following NiNTA chromatography were pooled, diluted three times with 
buffer (5 mM potassium phosphate, pH 7.4, with 20% glycerol, 4.8 mM Cymal-5, and 1 mM 
EDTA) to reduce the ionic strength, and loaded onto a HiTrap CM-Sepharose Fast Flow column 
that had been equilibrated with the same buffer. A ten-column-volume wash with CM wash 
buffer (50 mM potassium phosphate pH 7.4, 1 mM EDTA, 20% glycerol) was used to remove 
impurities and detergent, and the P450 protein was eluted from the column with a buffer 
containing high salt (50 mM potassium phosphate, pH 7.4, 20% glycerol, 500 mM NaCl, 1 mM 
EDTA). The final concentrations of P450 proteins were determined using the absolute 
absorbance at 417 nm and the reduced carbon monoxide difference spectrum. 
Spectroscopic Analysis for the Quantitation of Cytochrome P450 
The absolute absorption and reduced carbon monoxide difference spectra were both 
collected using a UV-2101 UV-visible scanning spectrophotometer (Shimadzu Scientific 
Instruments, Inc., Columbia, MD) and the general methods of Omura and Sato.5 To determine 
the absolute absorption, buffer corresponding to the protein sample (800 µL) was placed into a 
cuvette, the absorbance at 700 nm was set to zero, and a baseline was collected from 700-250 
nm. Protein sample (100 µL) was then added to the cuvette and mixed with the buffer by 
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inversion. The absorbance at 700 nm was set to zero a final time before the sample was scanned 
from 700-250 nm. The sample was analyzed to determine the concentration of P450 present 
using Beer’s Law: c = A / ε * l where c is the concentration in µM, l is the pathlength (1 cm), A 
is the absorption, and ε is the extinction coefficient (0.100 µM-1 cm-1). 
To determine the reduced carbon monoxide difference spectrum, 100 µL of protein 
solution was diluted into 800 µL of buffer corresponding to the protein sample in a 1 cm 
pathlength cuvette. The protein sample was reduced by the addition of a small amount of 
dithionite, mixed by inversion, and placed into the spectrophotometer. The absorbance at 500 nm 
was set to zero, and a baseline was collected from 500-400 nm. The reduced sample was 
removed from the spectrophotometer and further prepared by introducing ~50 bubbles of carbon 
monoxide into the solution. The sample was then returned to the spectrophotometer, the 
absorbance at 500 nm set to zero, and the difference spectrum from 500-400 nm measured. As 
necessary, the spectrum was measured every few minutes until the increase in absorbance at 450 
nm reached a maximum. The sample was analyzed to determine the concentration of P450 
present using Beer’s Law: c = A / ε * l where c is the concentration in µM, l is the pathlength (1 
cm), A is the absorption, and ε is the extinction coefficient (0.091 µM-1 cm-1). 
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Chapter 3 
Evaluation of Inhibition Selectivity for Human Cytochrome P450 2A Enzymes 
Introduction 
While xenobiotic metabolism by cytochrome P450 enzymes is often a detoxifying event, 
P450 enzymes can also activate toxins and procarcinogens.  To evaluate the involvement of 
individual P450 enzymes in drug metabolism or activation of potentially harmful chemical 
agents in vivo, a test compound is often incubated with human microsomes in the presence and 
absence of potent and selective inhibitors for the individual P450 enzymes expressed therein.  
This phenotyping process is widely used, but is critically dependent on the selectivity of the 
inhibitors employed. Despite the substantial overlapping substrate selectivity demonstrated by 
xenobiotic-metabolizing P450 enzymes, broad efforts have resulted in the identification of 
sufficiently selective inhibitors for many of the major human hepatic P450 enzymes, including 
CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.1 
In extrahepatic tissues, however, discrimination between the roles of individual P450 
enzymes is much more difficult for two reasons: 1) information about the expression of 
individual P450 proteins in the given tissue is often incomplete and 2) selective inhibitors are not 
well developed for most non-hepatic P450 enzymes.  This is particularly true in the human lung 
and respiratory tract, where at least 16 human P450 enzymes may play a crucial role in the 
balance between the detoxification and activation of inhaled compounds including environmental 
pollutants, industrial chemicals, therapeutic agents, and chemicals in cigarette smoke.2,3  
In lung tissue, the dissection of individual P450 contributions can be difficult because 
more than one protein from the same P450 subfamily is often present and their activities can be 
very similar. This is the case with the CYP2A6 and CYP2A13 enzymes of the CYP2A family, 
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whose detection is complicated by the cross-reactive nature of commercially available CYP2A 
antibodies.4 As a result, reliable information about relative CYP2A expression has been derived 
from mRNA. CYP2A13 is expressed to a greater extent in the respiratory tract, with ~5-fold 
higher mRNA levels in nasal mucosa and ~9-fold higher mRNA levels in lung compared to 
CYP2A6.4 In contrast, CYP2A6 expression is higher in human liver, with mRNA levels 
exceeding CYP2A13 by ~1900-fold.4 Thus, the relative contribution of CYP2A13 metabolism 
and inhibition is likely to be negligible in human liver microsomes, while both CYP2A enzymes 
may have substantial contribution in respiratory tract microsomes depending on the substrate or 
inhibitor chosen. 
Dissecting the relative metabolic roles of the CYP2A enzymes is further complicated by 
the fact that CYP2A6 and CYP2A13 share an amino acid sequence identity of 94%.5 Although 
such a high identity lends itself to substantial overlapping substrate selectivity, the CYP2A 
enzymes also exhibit key functional differences.4,6-8 For example, while CYP2A6 has a ten-fold 
higher enzymatic efficiency (kcat/Km) compared to CYP2A13 for 7-hydroxylation of coumarin, 
CYP2A13 much more efficiently metabolizes nicotine and activates the tobacco-related 
procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in vitro.4,6 Thus, 
CYP2A13- and CYP2A6-selective inhibitors are not only needed to evaluate the metabolism of 
drugs and other xenobiotic compounds delivered via inhalation, but may also be relevant to 
studying the tissue-specific activation of procarcinogens in the lung.  
To evaluate the respective roles of the CYP2A enzymes in tissues such as the lung where 
both enzymes are expressed, CYP2A13- and CYP2A6-selective inhibitors are needed. A number 
of compounds were reported to selectively inhibit CYP2A6 before CYP2A13 was determined to 
be a functional member of the CYPA family, or have simply not been tested against CYP2A13. 
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These compounds include: phenethyl isothiocyanate (PEITC), 4-dimethylaminobenzaldehyde 
(DMABA), 8-methoxypsoralen (8-MOP), tranylcypromine, tryptamine, pilocarpine, (S)-nicotine, 
(R)-(+)-menthofuran, and β-nicotyrine.9-14 Although a few of these inhibitors have now been 
tested for their ability to inhibit CYP2A13, these studies were conducted using a variety of 
experimental methods and protein preparations that make it difficult to directly compare CYP2A 
inhibition selectivity.6,15,16 More recent work has identified several additional inhibitors 
reportedly selective for CYP2A6, but which have not been evaluated for their ability to inhibit 
CYP2A13.17  
To address this gap in knowledge, the following 
study was designed to evaluate traditionally employed 
CYP2A6-selective inhibitors for their ability to 
discriminate between CYP2A6 and CYP2A13 using 
parallel assays for the inhibition of para-nitrophenol (pNP) 
2-hydroxylation (Figure 3.1). The relative impact of these 
inhibitors on CYP2A6 and CYP2A13 function was 
evaluated by determining Ki values and modes of 
inhibition for each of the compounds against both enzymes, followed by the calculation of a 
selectivity factor. The results of these studies serve as the first explicit determination of the 
selectivity of these compounds for enzymes within the CYP2A family. This information can be 
used to identify inhibitors with the greatest potential for determining whether CYP2A6 or 
CYP2A13 is responsible for the metabolism or activation of compounds, such as tobacco-
derived NNK in the human respiratory tract.  
 
Figure 3.1 para-Nitrophenol 2-
hydroxylation catalyzed by human 
CYP2A enzymes. Oxidative metabolism 
of pNP by CYP2A enzymes produces 
the metabolite 4-NC. 
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Materials and Methods 
 
Inhibition Assays 
 
The compound para-nitrophenol (pNP) was the substrate for inhibition assays used to 
evaluate the selectivity of CYP2A inhibitors. pNP was employed instead of the more traditional 
CYP2A substrate coumarin because the CYP2A enzymes catalyze the metabolism of pNP with 
more similar catalytic efficiency compared to that of coumarin. CYP2A6 and CYP2A13 have 
respective catalytic efficiencies (kcat/Km) of 0.12 µM-1min-1 and 0.19 µM-1min-1 for the 
metabolism of pNP. In contrast, the catalytic efficiency for the metabolism of coumarin by 
CYP2A6 (0.53 µM-1min-1) is nearly 5-fold higher than that of CYP2A13 for the same reaction 
(0.11 µM-1min-1). The more similar catalytic efficiency that both enzymes demonstrate for the 
metabolism of pNP allows for a more straightforward analysis of the ability of each compound to 
inhibit CYP2A6 versus CYP2A13. 
pNP is converted to 4-nitrocatechol (4-NC) by both CYP2A6 and CYP2A13 (Figure 3.1). 
Inhibition assays used a reconstituted protein system (RPS) consisting of 50 pmol of purified 
CYP2A protein incubated with 200 pmol NADPH-cytochrome P450 reductase and 100 pmol 
cytochrome b5 for 20 minutes at room temperature prior to use. RPS was added to 100 mM 
potassium phosphate, pH 6.8, with the substrate pNP and the desired inhibitor for a total volume 
of 500 µL. Samples were pre-incubated at 37 °C for 3 minutes before initiating the reactions by 
the addition of 1 mM NADPH. Reactions were allowed to proceed for 10 minutes at 37 °C and 
were quenched with 300 µL of 20% trichloroacetic acid and placed on ice. Samples were 
centrifuged at 4,500 x g for 6 minutes to pellet the protein, and the amount of the 4-nitrocatechol 
(4-NC) product in the supernatant was determined by absorbance following HPLC separation on 
a Luna 5 µm C-18 column (Phenomenex, Torrance, CA). A mobile phase of 29% acetonitrile 
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and 0.2% acetic acid at 0.8 mL/min was used for separation, except for assays with the inhibitor 
DMABA, which required 26% methanol and 0.2% acetic acid. Detection of absorption at 345 
nm revealed elution of the 4-NC product at a retention time of ~6 minutes, while the pNP 
substrate eluted at ~9 minutes. The amount of metabolite was determined by comparing the 
product peak area to a standard curve of 4-NC (0 µM - 30 µM). For preliminary IC50 
determinations, CYP2A activity was tested at a range of eight to twelve inhibitor concentrations 
from 0-1000 µM at a substrate concentration of 800 µM. IC50 values were then used to determine 
the range of concentrations to be used for full kinetic analysis of each inhibitor. For Ki 
determination, incubations were performed with at least four different concentrations of inhibitor 
and at least eight different concentrations of substrate (0 µM - 800 µM).  Ki values are the global 
fit to at least two separate inhibition experiments. 
Kinetic Analysis 
The rate of metabolite formation (pmol of metabolite/min/pmol of P450) was plotted 
against substrate concentration (µM), and the data were initially fit to the Michaelis-Menten 
equation using GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA). Km and Vmax values 
were determined and used to assess the mode of inhibition for each compound.  Following this 
analysis, the data was re-fit to the appropriate inhibition equation to determine Ki values (Eq. 3 
for competitive inhibition, Eq. 4 for uncompetitive inhibition, and Eq. 5 for mixed inhibition). 
(3)   
(4)   
(5)   
KmObs = Km ! (1+[I ] /Ki )
VmaxApp =Vmax / (1+ I / AlphaKi )
VmaxApp =Vmax / (1+ I / (Alpha!Ki ))
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Goodness of fit was determined using the global R2 value of the nonlinear regression analysis 
and inspection of the residuals. A selectivity factor indicating preference for CYP2A6 versus 
CYP2A13 was calculated by taking the ratio of CYP2A13 Ki / CYP2A6 Ki. 
Results 
Enzyme Inhibition 
Nine compounds have been reported by others to selectively inhibit CYP2A6. These 
compounds include PEITC, DMABA, 8-MOP, tranylcypromine, tryptamine, pilocarpine, (S)-
nicotine, (R)-(+)-menthofuran, and β-nicotyrine,9-14 and were either identified before CYP2A13 
was determined to be a functional enzyme of the CYP2A subfamily or have simply not been 
tested against CYP2A13. As a result, parallel assays for the inhibition of pNP 2-hydroxylation 
were conducted with purified, recombinant CYP2A enzymes to evaluate the ability of each of 
these compounds to differentially inhibit CYP2A6 and CYP2A13. 
Each compound was initially evaluated based on its ability to inhibit CYP2A6 or CYP2A13 
at a single concentration. The percentage of enzyme activity remaining in the presence of 800 
µM pNP and 400 µM inhibitor is shown for the different inhibitors in Figure 3.2. Seven of the 
eight inhibitors tested under these conditions inhibited CYP2A6 and CYP2A13 within a range of 
2.2% to 64% remaining activity. The last inhibitor 8-MOP was not soluble at 400 µM for this 
comparison, but 3 µM 8-MOP effectively reduced the function of CYP2A6 to 24% remaining 
activity and CYP2A13 to 3.1% remaining activity. Aside from 8-MOP, the lowest activity 
remaining was observed in the presence of tranylcypromine for CYP2A6 and with pilocarpine 
for CYP2A13.  The most activity remaining for both enzymes was observed in the presence of 
(S)-nicotine.  In addition, (S)-nicotine, DMABA, pilocarpine, PEITC, and β-nicotyrine inhibited 
both CYP2A enzymes to similar extents, while 8-MOP, tryptamine, tranylcypromine, and 
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menthofuran showed varying selectivity for inhibition of CYP2A6 activity over CYP2A13 
activity.  
Comparison of each compound’s potency for inhibition of CYP2A6 versus CYP2A13 at a 
single concentration may not be reflective of inhibition over a range of concentrations due to the 
fact that the modality of inhibition may differ among these inhibitors and between the two 
enzymes examined. Thus, steady state kinetics were evaluated for both CYP2A6 and CYP2A13 
in the presence of each inhibitor and Ki values were determined (Table 3-1). For CYP2A6, Ki 
values varied from 0.13 to 130 µM, while Ki values for CYP2A13 ranged from 0.04 to 72 µM.  
Figure 3.2 Initial evaluation of the selective inhibition of nine previously described CYP2A6 inhibitors for 
CYP2A6 versus CYP2A13. Percentage of remaining activity is based on the amount of pNP (800 µM) 
metabolism to 4-NC in the presence of 400 µM of the various inhibitors shown. The symbol * indicates that the 
compound was not soluble at 400 µM in assay buffer. The compound 8-MOP was tested at a maximal 
concentration of 3 mM, at which point CYP2A6 and CYP2A13 were reduced to 24% and 3.1% of maximal 
activity, respectively. 
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Table 3-1. Results of steady state kinetic studies for the evaluation of CYP2A selectivity. Incubations were 
performed with recombinant, purified CYP2A6 or CYP2A13 reconstituted in a 1:4:2 ratio with P450 reductase and 
cytochrome b5 in the presence of four or more different concentrations of inhibitor and eight or more different 
concentrations of substrate (0 µM - 800 µM). Ki values are the global fit to at least two separate inhibition 
experiments. 
 
 
 
Inhibitor P450 Ki (µM) Mechanism (α) 
2A13 Ki 
2A6 Ki 
tranylcypromine 
2A13 6.5 ± 1.2 competitive 
49 
2A6 0.13 ± 0.02 mixed (α=10) 
  
(R)-menthofuran 
2A13 54 ± 12 mixed (α=4.3) 
27 
2A6 2.0 ± 0.44 mixed (α=4.3) 
tryptamine 
 
 
 
tryptamine  
2A13 16 ± 3.5 competitive 
9.4 
2A6 1.7 ± 0.12 competitive 
4-dim thylamino-
benzaldehyde (DMABA) 
2A13 17 ± 5.0 mixed (α=13) 
4.6 
2A6 3.6 ± 0.83 mixed (α=5.5) 
phenethyl isothiocyanate 
(PEITC) 
2A13 3.8 ± 1.6 mixed (α=0.20) 
2.2 
2A6 1.7 ± 0.28 mixed (α=270) 
  
 
 
 
β-nicotyrine 
β-nicotyrine 
2A13 5.6 ± 0.86 mixed (α=6.6) 
0.74 
2A6 7.5 ± 2.9 mixed (α=3.5) 
 
 
 
(S)-nicotine 
2A13 72 ± 4.6 competitive 
0.55 
2A6 130 ± 8.8 competitive 
pilocarpine 
2A13 1.4 ± 0.12 competitive 
0.47 
2A6 3.0 ± 0.45 mixed (α=25) 
8-methoxypsoralen  
(8-MOP) 
2A13 0.040 ± 0.009 mixed (α=1.9) 
0.16 
2A6 0.25 ± 0.10 mixed (α=3.3) 
O
NN
OOO
O
NH2
N
H
NH2
N
H
O
N C S
N
N
H
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The strongest inhibitors of CYP2A6 are tranylcypromine (Ki = 0.13 ± 0.02 µM) and 8-MOP (Ki 
= 0.25 ± 0.10 µM), both displaying submicromolar Ki values.  The inhibitor 8-MOP was the only 
inhibitor with a submicromolar Ki value for CYP2A13 (Ki = 0.04 ± 0.009 µM), with the next 
closest as PEITC (Ki =3.8 ± 1.6 µM).  The least potent inhibitor for CYP2A6 is (S)-nicotine (Ki = 
130 ± 8.8 µM).  For CYP2A13 both (S)-nicotine (Ki = 72 ± 4.6 µM) and (R)-(+)-menthofuran (Ki 
= 54 ± 12 µM) are the least effective inhibitors. 
Each of the compounds exhibited either competitive or mixed modes of inhibition, and most 
of the compounds exhibited the same mode of inhibition for both enzymes. (S)-Nicotine and 
tryptamine exhibited competitive modes of inhibition against both CYP2A6 and CYP2A13. 
Tranylcypromine and pilocarpine both exhibited competitive inhibition with CYP2A13, while 
mixed inhibition was the best model for these compounds with CYP2A6. The remaining 
compounds ((R)-(+)-menthofuran, DMABA, PEITC, β-nicotyrine, and 8-MOP) demonstrated 
mixed inhibition for both enzymes. While the alpha values for the mixed inhibitors (R)-(+)-
menthofuran, DMABA, β-nicotyrine and 8-MOP are fairly close in value for the two enzymes, a 
large difference in the alpha values were observed for PEITC. An alpha value of 270 in the case 
of CYP2A6 suggests that PEITC binds primarily to the free enzyme (E state), while a much 
smaller alpha value of 0.20 in the case of CYP2A13 indicates that PEITC binds primarily to the 
enzyme-substrate complex (ES state). The contrasting modes of inhibition that PEITC 
demonstrates for CYP2A6 versus CYP2A13 are illustrated in Figure 3.3. The selectivity of these 
compounds to inhibit enzyme activity was determined by calculating the ratio of the CYP2A13 
Ki to the CYP2A6 Ki (Table 1). Of the nine compounds examined, only (R)-(+)-menthofuran and 
tranylcypromine have a greater than 10-fold preference for CYP2A6 inhibition over CYP2A13. 
Tranylcypromine demonstrates the highest preference for CYP2A6 with a selectivity factor of  
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49, followed by (R)-(+)-menthofuran with a selectivity factor of 27. DMABA and tryptamine 
have more moderate selectivity for CYP2A6, with selectivity factors of ~5-10. The remaining 
inhibitors have less than ~2-fold preference for either of the CYP2A enzymes, with the exception 
of 8-MOP. 8-MOP demonstrated a 6-fold preference for inhibition of CYP2A13 over CYP2A6.  
Discussion 
 
Kinetic analysis for the inhibition of pNP 2-hydroxylation was used to evaluate a 
chemically diverse set of known CYP2A6 inhibitors to determine which are able to discriminate 
effectively between CYP2A6 and CYP2A13. The evaluation of the selectivity of these 
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Figure 3.3. PEITC demonstrates extremes of mixed inhibition for CYP2A6 versus CYP2A13. CYP2A6 
inhibition by PEITC results in a much larger effect on the Km values, as shown in the Michaelis-Menten (A) and 
Lineweaver-Burk (B) plots, suggesting much higher affinity for the E state (α=270). For CYP2A13, however, 
Michaelis-Menten (C) and Lineweaver-Burk (D) plots illustrate that PEITC inhibition has a larger effect on the Vmax, 
suggesting much tighter binding to the ES state (α=0.20). 
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compounds for both enzymes within the human CYP2A family employed parallel assays under 
identical experimental conditions with recombinant, purified proteins. Among the most selective 
enzyme inhibitors tested were tranylcypromine and (R)-(+)-menthofuran, which demonstrate a 
49-fold and 27-fold preference for CYP2A6 inhibition over CYP2A13, respectively. Tryptamine 
and DMABA were only moderately (5- to 10-fold, respectively) selective for CYP2A6 
inhibition. 
The monoamine oxidase inhibitor tranylcypromine is a potent inhibitor of CYP2A6 and 
is commonly used for P450 phenotyping, but the selectivity of the compound has been reported 
by several others as less than ideal.1 In a study conducted to characterize the inhibitory 
selectivity of tranylcypromine in human liver microsomes, Taavitsainen and colleagues 
determined that the Ki value of tranylcypromine for CYP2A6 is 16- to 17-times lower than the 
next most potently inhibited enzymes, CYP2C19 and CYP2E1.18 This is a much narrower range 
than the 49-fold difference in CYP2A6 Ki versus CYP2A13 Ki reported herein. Thus, 
tranylcypromine may have utility in studies that seek to discriminate between CYP2A6 and 
CYP2A13 activity, but the compound fails to discriminate sufficiently among liver CYP450 
enzymes, as demonstrated previously. 
(R)-(+)-Menthofuran was first reported in 1998 by Khojasteh-Bakht and colleagues as a 
potent, mechanism-based highly selective inhibitor of human CYP2A6.10 Since then, it has been 
used in various P450 phenotyping studies to selectively inhibit CYP2A6.19,20 The Ki value of 2.0 
± 0.44 µM herein agrees well with 2.5 µM reported for CYP2A6 in human liver microsomes by 
Khojasteh-Bakht and colleagues, but is slightly higher than the Ki value of 0.84 µM reported 
elsewhere for reconstituted purified CYP2A6 enzyme.10 Based on inhibition of pNP 2-
hydroxylation in reactions similar to those typically used for P450 phenotyping, menthofuran 
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was one of the more selective of the traditionally employed CYP2A6 inhibitors when 
specifically discriminating enzyme activity within CYP2A family.  
Tryptamine is a trace amine found in the brain that serves as a precursor to the 
neurotransmitter serotonin and the hormone melatonin. Tryptamine demonstrated a competitive 
mode of inhibition for both CYP2A6 and CYP2A13. The Ki value of tryptamine for CYP2A6 of 
1.7 µM is identical to the value reported by Zhang and colleagues in cDNA-expressing 
microsomes using coumarin 7-hydroxylase activity.14 However, the preference of tryptamine for 
the inhibition of CYP2A6 over CYP2A13 difference is less than ten-fold, making it an 
undesirable candidate for effectively distinguishing between the activities of the two enzymes.  
DMABA is an inhibitor reported to be selective for CYP2A6.13 Inhibition studies of this 
compound using human liver microsomes indicated >20-fold selectivity for CYP2A6 over all 
other hepatic cytochrome P450 enzymes, with the exception of CYP2E1 where the DMABA is 
only 13-fold selective for CYP2A6.13 The reported IC50 for CYP2A6 was 0.45 µM, but 
CYP2A13 was not evaluated in that work. We observed only a very moderate 4.6-fold selectivity 
for CYP2A6 over CYP2A13, making DMABA an inappropriate inhibitor for distinguishing 
between the activities of CYP2A6 and CYP2A13 in respiratory tract and other tissues that 
express both enzymes. 
The remaining compounds preferentially inhibited CYP2A13 or demonstrated relatively 
little preference for either CYP2A6 or CYP2A13. PEITC, (S)-nicotine, β-nicotyrine, pilocarpine, 
and 8-MOP all have selectivity factors ranging from 0.16 to 2.2. 
PEITC is one of the most extensively studied compounds of the isothiocyanate class of 
compounds. Isothiocyanates such as PEITC are found in high levels in cruciferous vegetables 
such as cauliflower, Brussels sprouts, and watercress. PEITC is considered to act as a 
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chemopreventative agent through the inhibition of P450 enzymes involved in the activation of 
procarcinogens, such as the activation of the tobacco-derived procarcinogen NNK by enzymes of 
the CYP2A family.12,21,22 PEITC has been reported to potently inhibit both CYP2A6 and 
CYP2A13 with sub-micromolar Ki values,15 and was found in this study to demonstrate a two-
fold preference for the inhibition of CYP2A13 over CYP2A6 with Ki values of 3.8 µM and 1.7 
µM for the two enzymes, respectively. 
The tobacco alkaloids (S)-nicotine and β-nicotyrine are structurally similar and 
demonstrate a similar lack of selectivity among human CYP2A enzymes. The major tobacco 
alkaloid (S)-nicotine is the primary mediator of the pharmacological effects and addiction 
liability of smoking and is a known substrate for both CYP2A enzymes. The competitive mode 
of inhibition that (S)-nicotine demonstrates is consistent with the fact that it is a known substrate 
for both CYP2A enzymes. The nicotine-related tobacco alkaloid β-nicotyrine is a potent, 
mechanism-based inactivator of CYP2A6, although its inhibitory activity is not selective for 
CYP2A6.9 Both compounds demonstrate a slight preference for the inhibition of CYP2A13 over 
CYP2A6, but the difference in Ki values for both compounds are less than two fold.  
Pilocarpine is a natural alkaloid found in the leaves of P. microphyllus and is used 
therapeutically as a non-selective muscarinic receptor agonist to control elevated intraocular 
pressure associated with glaucoma. It has been previously determined by others to inhibit 
CYP2A and CYP2B activities more efficiently than other P450 activities in vitro.23 Our studies 
confirm that pilocarpine is a potent inhibitor of CYP2A enzymes, with Ki values of 3.0 µM and 
1.4 µM for CYP2A6 and CYP2A13, respectively. Pilocarpine inhibits the two closely related 
CYP2A enzymes using similar but not identical mechanisms of inhibition, acting as a 
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competitive inhibitor for CYP2A13 and as a mixed inhibitor for CYP2A6 with higher affinity for 
the E state (α=25). 
The compound that demonstrated the most selectivity for CYP2A13 inhibition with a 
selectivity factor of 0.16 is 8-MOP (also known as methoxsalen or xanthotoxin). Inhibition of 
CYP2A6 and CYP2A13 resulted in a decrease in the Vmax and an increase in the Km, suggesting a 
mixed mode of inhibition for both enzymes, with alpha values of 3.3 and 1.9 for CYP2A6 and 
CYP2A13, respectively. Previous reports have identified 8-MOP as a noncompetitive inhibitor 
for both CYP2A enzymes.14,16 Our study also confirms that 8-MOP more potently inhibits 
CYP2A13, with a Ki value of 0.04 µM versus 0.25 µM for CYP2A6. This 6-fold degree of 
selectivity is greater than the 1.8-fold difference previously indicated according to results 
published in separate studies.14,16 
Conclusion 
 
The goal of this study was to compare, side-by-side, a set of reportedly CYP2A6-
selective inhibitors to determine their relative ability to discriminate between CYP2A6 and the 
94% identical enzyme CYP2A13, and thus their utility in distinguishing between CYP2A 
activities in tissues where both enzymes are present. The ratio of CYP2A13 Ki / CYP2A6 Ki for 
each compound revealed that tranylcypromine and (R)-(+)-menthofuran are the most selective 
inhibitors for CYP2A6, but that they have only 49- and 27-fold selectivity for CYP2A6 over 
CYP2A13, respectively. Even though the ability of tranylcypromine to distinguish between 
CYP2A enzymes is not ideal, this compound can be used as a benchmark for the development of 
more selective inhibitors. Six of the compounds tested demonstrated only moderate or no real 
selectivity between the human CYP2A enzymes. Thus, these compounds should not be 
employed to evaluate individual CYP2A enzyme contributions to metabolism in tissues where 
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both enzymes may be present. This study did not identify a suitably selective inhibitor for 
CYP2A13. The 6-fold selectivity of 8-MOP for CYP2A13 over CYP2A6 is marginal at best, but 
does provide a starting point for the development of a more selective inhibitor. Altogether, these 
results can be used as a guide for the selection of CYP2A-selective inhibitors in studies that seek 
to accurately distinguish between CYP2A6 and CYP2A13 activity.  Such efforts are particularly 
relevant in evaluations of the in vivo activation of compounds that give rise to tissue-specific 
carcinogenesis, such as tobacco-derived NNK in the human respiratory tract. 
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Chapter 4 
Expression and Purification of the Cytochrome P450 26 Family of Enzymes 
Introduction 
 The CYP26 family of cytochrome P450 enzymes are important mediators of retinoic acid 
(RA) catabolism in the body. Biologically active retinoids are essential signaling molecules that 
control various developmental pathways and influence the proliferation and differentiation of a 
variety of cell types.1,2 The proper function of these pathways relies upon the body’s ability to 
maintain precise control of retinoic acid levels, particularly the biologically most active isomer 
all-trans-retinoic acid (atRA).3 
The human CYP26 family consists of three enzymes that share an amino acid sequence 
identity of 42-51%: CYP26A1, CYP26B1, and CYP26C1.4 All three members of the CYP26 
family are capable of metabolizing atRA to the major oxidative metabolites 4-hydroxy-atRA, 4-
oxo-atRA, and 18-hydroxy-atRA (Figure 4.1).5-7 CYP26A1 and CYP26B1 share similar 
substrate specificities, with high catalytic activity toward atRA and much lower activity towards 
9-cis-RA and 13-cis-RA.8 The expression and metabolic function of these two enzymes are also 
inducible by the presence of atRA, likely serving as a feedback loop for the auto-regulation of 
RA levels.8,9 In contrast, CYP26C1 has the ability to bind and oxidize both 9-cis-RA and atRA 
equally and is much more effectively induced by 9-cis-RA than atRA.10  
Retinoids such as atRA represent attractive targets for medicinal intervention due to their 
capacity to serve as differentiating agents, redirecting cells toward their normal phenotype. atRA 
itself has been successfully used for cancer chemoprevention, chemotherapy, differentiation 
therapy, and for the treatment of acne.3 One of the most impressive effects of atRA therapy is in 
respect to promyelocytic leukemia, with patients achieving full remission after treatment with 
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high doses of atRA.11 Unfortunately, atRA-based therapies tend to fail with continuous use due 
to the development of resistance.12 This failure has been suggested to be the result of up-
regulation of P450 enzymes, particularly the enzymes of the CYP26 family,9,13 resulting in 
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Figure. 4.1 Retinoic acid metabolism by CYP26 enzymes. All three members of the human CYP26 family are able 
to convert atRA to 4-hydroxy-atRA, 4-oxo-atRA, and 18-hydroxy-atRA. CYP26A1 and CYP26B1 exhibit very high 
catalytic activity toward atRA and much lower activity toward 9-cis-RA and 13-cis-RA, while CYP26C1 demonstrates 
an equal ability to catalyze the oxidation of 9-cis-RA and atRA. 
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enhanced in vivo atRA metabolism.14,15 As a result, a significant amount of work has been 
conducted for the development of chemical agents that inhibit P450-mediated metabolism of 
atRA, commonly referred to as retinoic acid metabolism blocking agents (RAMBAs).3,16-18 
 Unfortunately, the exact metabolic pathway and kinetics of RA metabolism, as well as 
specific structural information of CYP26 enzymes, are lacking due to the inability to generate 
sufficient amounts of recombinant enzyme necessary for characterization. As members of the 
P450 family, the CYP26 proteins are membrane-bound proteins localized within the endoplasmic 
reticulum. This characteristic makes them particularly difficult to express and isolate on a large 
scale. As a result, a majority of studies have relied on assays conducted with transfected cells or 
microsomal fractions prepared from tissue samples or cultured cells.5,19-22 The scarce quantities 
and heterogeneous nature of these P450 preparations significantly limit the extent of structural 
and functional information that can be determined. 
Thus, the immediate goal of this project was to construct a method that would enable the 
production of a recombinant CYP26 enzyme with yield and purity that exceeded current 
approaches. Although human CYP26A1 represented the original target, the studies were soon 
expanded to include all three CYP26 enzymes in human and in mouse in hopes that an expanded 
investigation would increase the chances of successfully generating any one CYP26 enzyme for 
characterization studies. With limited precedence in the literature for the generation of CYP26 
proteins, the techniques used were heavily based on methods applied to the successful expression 
and purification of other P450 proteins,23 including those of the CYP2A family.24,25 As a result, 
E. coli was selected as an expression host, and the amino acid sequence of each of the CYP26 
proteins was specifically modified to facilitate expression via truncation of the N-terminal 
transmembrane helix. Additional modifications were made to enhance the solubility of the 
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CYP26 proteins and make them amenable to metal affinity chromatography, thereby promoting 
ease of purification. Finally, optimization of the purification of the CYP26 proteins involved 
careful selection of the most promising detergents and stabilizing ligands based on available 
information in the literature. Altogether, the combination of these approaches had the potential to 
facilitate basic structural and kinetic determination studies, ultimately serving as a basis for 
improved modulation of atRA levels as a form of cancer treatment. 
Materials and Methods 
Engineering of Plasmid DNA 
 The cDNAs coding for each of the CYP26 enzymes were acquired from a variety of 
sources. Each of the cDNAs coded for the full-length, wild-type versions of the CYP26 proteins, 
except for the human CYP26A1 cDNA which was synthesized with the modifications described 
below already in place. A synthetic, codon optimized gene coding for human CYP26A1 was 
purchased from Blue Heron Biotechnology (Bothell, WA) and received in a pUCminusMCS 
plasmid. Human CYP26B1 cDNA was purchased from Open Biosystems (Lafayette, CO) and 
received in a pPCR-Script Amp SK(+) plasmid. Human CYP26C1 cDNA was acquired as a 
generous gift from Dr. Christian Helvig at Cytochroma in a pcDNA3.1+ plasmid. Mouse 
CYP26A1, CYP26B1, and CYP26C1 cDNA were all acquired as a generous gift from Dr. Alex 
Moise at The University of Kansas in a pcDNA3.1/V5-His-TOPO plasmid. 
 The cDNAs for each of the CYP26 enzymes were transformed into chemically competent 
DH5α E. coli cells by heat shock for 40 seconds at 42 °C in 1.5 mL microcentrifuge tubes 
following a 40 minute incubation with the plasmid DNA on ice. The cells were then allowed to 
recover on ice for a few minutes before they were plated on Lysogeny Broth (LB)-ampicillin 
agar plates containing 50 µg/mL ampicillin and grown overnight. The next day, individual 
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colonies containing full length CYP26 plasmid DNA were isolated from the LB-ampicillin agar 
plates and grown overnight at 37 °C in 5 mL LB cultures containing 50 µg/mL ampicillin. The 
cells from the overnight 5 mL LB-ampicillin cultures were pelleted by centrifugation and the 
supernatant was decanted. Plasmid DNA was purified using the QIAprep Spin Miniprep Kit 
from Qiagen, according to the manufacturer’s protocol.  
CYP26 Protein Modification and Cloning 
Mammalian membrane cytochrome P450 enzymes have a single N-terminal 
transmembrane helix followed by a proline-rich region and membrane-bound catalytic domain. 
While the transmembrane helix can often be truncated, the proline-rich region is often necessary 
for protein stability. The CYP26 proteins were each engineered for enhanced expression in E. 
coli and ease of purification through truncation of the N-terminal transmembrane sequence, 
modification of the N-terminus with the addition of a short hydrophilic sequence, and addition of 
four histidine residues to the C-terminus. To determine the extent of the desired N-terminal 
truncation for the CYP26 enzymes, an alignment was performed using CLC sequence viewer 
6.5.4 with human CYP26A1 and several other human P450 proteins that have been successfully 
truncated, expressed, and purified by previous members of the research group: CYP2A6, 
CYP2A13, and CYP2E1 (Figure. 4.2). The same truncation was applied to all six human and 
mouse CYP26 cDNAs. All work described herein has been conducted with these truncated, His-
tagged versions of the CYP26 enzymes An alignment of all six full-length CYP26 proteins prior 
to modification is shown in Figure. 4.3.   
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         10      20        30         40           50      60 
humanCYP26A1        M---GLPAL- -LASALCTFV LPLLLFLAAI KLWDLYCVSG RDRSCALPLP PGTMGFPFFG 55 
humanCYP26B1        MLFEGLDLVS ALATLAACLV SVTLLLAVSQ QLWQLRWAAT RDKSCKLPIP KGSMGFPLIG 60 
humanCYP26C1        MFPWGLSCLS VLGAAGTALL CAGLLLSLAQ HLWTLRWMLS RDRASTLPLP KGSMGWPFFG 60 
mouseCYP26A1        M---GLPAL- -LASALCTFV LPLLLFLAAL KLWDLYCVSS RDRSCALPLP PGTMGFPFFG 55 
mouseCYP26C1        MISWGLSCLS VLGAAGTTLL CAGLLLGLAQ QLWTLRWTLS RDWASTLPLP KGSMGWPFFG 60 
mouseCYP26B1        MLFEGLELVS ALATLAACLV SVTLLLAVSQ QLWQLRWAAT RDKSCKLPIP KGSMGFPLIG 60 
                    *   **  :   *.:    ::    **:  :  :** *      ** :. **:*  *:**:*::* 
         70       80        90        100     110     120 
humanCYP26A1        ETLQMVLQRR KFLQMKRRKY GFIYKTHLFG RPTVRVMGAD NVRRILLGEH RLVSVHWPAS 115 
humanCYP26B1        ETGHWLLQGS GFQSSRREKY GNVFKTHLLG RPLIRVTGAE NVRKILMGEH HLVSTEWPRS 120 
humanCYP26C1        ETLHWLVQGS RFHSSRRERY GTVFKTHLLG RPVIRVSGAE NVRTILLGEH RLVRSQWPQS 120 
mouseCYP26A1        ETLQMVLQRR KFLQMKRRKY GFIYKTHLFG RPTVRVMGAD NVRRILLGEH RLVSVHWPAS 115 
mouseCYP26C1        ETLHWLVQGS RFHSSRRERY GTVFKTHLLG RPVIRVSGAE NVRTILLGEH RLVRSQWPQS 120 
mouseCYP26B1        ETGHWLLQGS GFQSSRREKY GNVFKTHLLG RPLIRVTGAE NVRKILLGEH QLVSTEWPRS 120 
                    ** : ::*    * . :*.:* * ::****:* ** :** **: *** **:*** :**  .** * 
        130      140       150         160          170     180 
humanCYP26A1        VRTILGSGCL SNLHDSSHKQ RKKVIMRAFS REALECYVPV ITEEVGSSLE QWLSCGERGL 175 
humanCYP26B1        TRMLLGPNTV SNSIGDIHRN KRKVFSKIFS HEALESYLPK IQLVIQDTLR AWSSHPE-AI 179 
humanCYP26C1        AHILLGSHTL LGAVGEPHRR RRKVLARVFS RAALERYVPR LQGALRHEVR SWCAAGG-PV 179 
mouseCYP26A1        VRTILGAGCL SNLHDSSHKQ RKKVIMQAFS REALQCYVPV IAEEVSSCLE QWLSCGERGL 175 
mouseCYP26C1        AHILLGSHTL LGAVGEPHRQ RRKVLARVFS RSSLEQFVPR LQGALRREVR SWCAAQR-PV 179 
mouseCYP26B1        ARVLLGPNTV ANSIGDIHRN KRKVFSKIFS HEALESYLPK IQLVIQDTLR AWSSQPE-AI 179 
                    .: :**.  :  .  .. *:. ::**: : ** : :*: ::* :   :   :.  * :     : 
         190      200       210        220         230           240 
humanCYP26A1        LVYPEVKRLM FRIAMRILLG CEPQLAGDGD SEQQLVEAFE EMTRNLFSLP IDVPFSGLYR 235 
humanCYP26B1        NVYQEAQKLT FRMAIRVLLG FSIPEEDLGH ----LFEVYQ QFVDNVFSLP VDLPFSGYRR 235 
humanCYP26C1        SVYDASKALT FRMAARILLG LRLDEAQCAT ----LARTFE QLVENLFSLP LDVPFSGLRK 235 
mouseCYP26A1        LVYPEVKRLM FRIAMRILLG CEPGPAGGGE DEQQLVEAFE EMTRNLFSLP IDVPFSGLYR 235 
mouseCYP26C1        AVYQAAKALT FRMAARILLG LQLDEARCTE ----LAHTFE QLVENLFSLP LDVPFSGLRK 235 
mouseCYP26B1        NVYQEAQRLT FRMAVRVLLG FSIPEEDLGH ----LFEVYQ QFVENVFSLP VDLPFSGYRR 235 
                     **   : *  **:* *:***               * ..::: :. *:****: *:****  : 
         250       260       270        280         290          300 
humanCYP26A1        GMKARNLIHA RIEQNIRAKIC GLRASEAGQ GCKDALQLLI EHSWERGERL DMQALKQSST 295 
humanCYP26B1        GIQARQILQK GLEKAIREKLQ CTQGKDYL- ---DALDLLI ESSKEHGKEM TMQELKDGTL 291 
humanCYP26C1        GIRARDQLHR HLEGAISEKLH EDKAAEPG- ---DALDLII HSARELGHEP SMQELKESAV 291 
mouseCYP26A1        GVKARNLIHA RIEENIRAKIR RLQATEPDG GCKDALQLLI EHSWERGERL DMQALKQSST 295 
mouseCYP26C1        GIRARDQLYE HLDEAVAEKLQ EKQTAEPG- ---DALLLII NSARELGHEP SVQELKELAV 291 
mouseCYP26B1        GIQARQILQK GLEKAIREKLQ CTQGKDYS- ---DALDILI ESSKEHGKEM TMQELKDGTL 291 
                    *::**: :    ::  :  *:    :  :       *** ::* . : * *..   :* **: :  
         310     320      330        340         350          360 
humanCYP26A1        ELLFGGHETT ASAATSLITY LGLYPHVLQK VREELKSKGL L--------- ---------- 336 
humanCYP26B1        ELIFAAYATT ASASTSLIMQ LLKHPTVLEK LRDELRAHGI LH-------- SGG------- 336 
humanCYP26C1        ELLFAAFFTT ASASTSLVLL LLQHPAAIAK IREELVAQGL GRACGCAPGA AGGSEGPPPD 351 
mouseCYP26A1        ELLFGGHETT ASAATSLITY LGLYPHVLQK VREEIKSKGL L--------- ---------- 336 
mouseCYP26C1        ELLFAAFFTT ASASTSLILL LLQHPAAITK IQQELSAQGL GRACTCTPRA SGS----PPD 347 
mouseCYP26B1        ELIFAAYATT ASASTSLIMQ LLKHPAVLEK LREELRAQGL LH-------- GGG------- 336 
                    **:*... ** ***:***:   *  :* .: * :::*: ::*:                       
         370     380      390        400         410          420 
humanCYP26A1        CKSNQDNKLD MEILEQLKYI GCVIKETLRL NPPVPGGFRV ALKTFELNGY QIPKGWNVIY 396 
humanCYP26B1        CPCEGT--LR LDTLSGLRYL DCVIKEVMRL FTPISGGYRT VLQTFELDGF QIPKGWSVMY 394 
humanCYP26C1        CGCEPD--LS LAALGRLRYV DCVVKEVLRL LPPVSGGYRT ALRTFELDGY QIPKGWSVMY 409 
mouseCYP26A1        CKSNQDNKLD METLEQLKYT GCVIKETLRL NPPVPGGFRV ALKTFELNGY QIPKGWNVIY 396 
mouseCYP26C1        CGCEPD--LS LAMLGRLRYV DCVVKEVLRL LPPVSGGYRT ALRTFELDGY QIPKGWSVMY 405 
mouseCYP26B1        CPCEGT--LR LDTLSSLRYL DCVIKEVMRL FTPVSGGYRT VLQTFELDGF QIPKGWSVMY 394 
                    * .:    *  :  *  *:*  .**:**.:**  .*:.**:*. .*:****:*: ******.*:* 
         430     440      450        460         470          480 
humanCYP26A1        SICDTHDVAE IFTNKEE-FN PDRFMLPHPE D---ASRFSF IPFGGGLRSC VGKEFAKILL 452 
humanCYP26B1        SIRDTHDTAP VFKDV-NVFD PDRFSQARSE DK--DGRFHY LPFGGGVRTC LGKHLAKLFL 451 
humanCYP26C1        SIRDTHETAA VYRSPPEGFD PERFGAARED SRGASSRFHY IPFGGGARSC LGQELAQAVL 469 
mouseCYP26A1        SICDTHDVAD IFTNKEE-FN PDRFIVPHPE D---ASRFSF IPFGGGLRSC VGKEFAKILL 452 
mouseCYP26C1        SIRDTHETAA VYRSPPEGFD PERFGVESGD ARGSGGRFHY IPFGGGARSC LGQELAQAVL 465 
mouseCYP26B1        SIRDTHDTAP VFKDV-NVFD PDRFSQARSE DK--DGRFHY LPFGGGVRTC LGKHLAKLFL 451 
                    ** ***:.*  :: .  : *: *:**     :      .** : :***** *:* :*:.:*: .* 
         490     500      510        520         530          540 
humanCYP26A1        KIFTVELARH CDWQLLNGP- PTMKTSPTVY PVDNLPARFT HFHGE----- ---------- 496 
humanCYP26B1        KVLAVELAST SRFELATRTF PRITLVPVLH PVDGLSVKFF GLDSNQNEIL PETEAMLSAT 511 
humanCYP26C1        QLLAVELVRT ARWELATPAF PAMQTVPIVH PVDGLRLFFH PL-------- TPSVAGNGLC 521 
mouseCYP26A1        KIFTVELARH CDWQLLNGP- PTMKTSPTVY PVDNLPARFT HFQGD----- ---------- 496 
mouseCYP26C1        QLLAVELVRT ARWELATPAF PVMQTVPIVH PVDGLLLFFH PL-------- PTSGAGDGLP 517 
mouseCYP26B1        KVLAVELAST SRFELATRTF PRITLVPVLH PVDGLSVKFF GLDSNQNEIL PETEAMLSAT 511 
                    ::::***.   . ::* . .  * :   * :: ***.*   *   :                   
 
humanCYP26A1        I 497 
humanCYP26B1        V 512 
humanCYP26C1        L 522 
mouseCYP26A1        I 497 
mouseCYP26C1        F 518 
mouseCYP26B1        V 512 
                    . 
Figure 4.3. Sequence alignment of CYP26A1, CYP26B1, and CYP26C1 in mouse and human. Sequence 
identity among enzymes in the CYP26 family is 42-53%, while sequence identity of the same enzymes between the 
two species is 87-93%. Residue conservation is coded as follows: “*” : identical, “:” : conserved substitution, “.” : 
semi-conserved substitution. 
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Synthetic oligonucleotide primers were designed to confer the desired modifications upon 
each full-length CYP26 cDNA. The forward and reverse oligonucleotide primers shown in Table 
4-1 contain nucleotides encoding the desired amino acid changes as well as a region of 
complementary sequence. Each forward primer was designed to add the hydrophilic tag 
‘MAKKTSSKGK’ to the truncated N-terminus, while each reverse primer was designed to add a 
four-histidine tag after the last native residue. All forward and reverse primers also included 
specific restriction sites for insertion into the P450 expression plasmid pKK233-2 (Pharmacia, 
Stockholm, Sweden). For every CYP26 cDNA other than human CYP26A1, this required 
deletion of an intrinsic and undesired NcoI restriction enzyme recognition site and the 
simultaneous generation of a new NcoI site. 
The oligonucleotide primers were annealed to the respective full-length cDNAs and 
extended to generate truncated, His-tagged versions of the CYP26 genes using Finnzymes 
Phusion High-Fidelity DNA Polymerase (Thermo Scientific Inc., Waltham, MA) during PCR 
using a PCR Sprint Thermal Cycler (Thermo Scientific Inc., Waltham, MA). Each reaction was 
divided into 3 segments (see Table 4-2). The same thermal cycling conditions were used for the 
successful modification of each of the CYP26 genes except for human CYP26C1. For human 
CYP26C1, a lack of product formation could possibly be a result of the very strong secondary 
structure of the forward primer. To troubleshoot this issue, several modifications were made to 
the initial thermal cycling conditions, including: the use of a modified polymerase buffer 
designated for GC rich templates, the addition of a longer initial denaturing cycle of 3 minutes, 
extended denaturing and extension steps in the second segment, and 40 repeats of the second 
segment of cycling instead of 30. 
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Following PCR, the ~1.5 kb fragment containing each modified CYP26 cDNA template 
was cut with the restriction enzymes NcoI and EcoRV or NcoI and HindIII in preparation for 
ligation into similarly digested pKK233-2. Each CYP26 DNA fragment was ligated into 
pKK233-2 in a 5 minute reaction conducted at room temperature using Roche’s ‘Rapid DNA 
Ligation Kit’ with pKK233-2:CYP26 ratios ranging from 1:1 to 1:6. Following the brief ligation 
reaction, 1.5 µL of each reaction mixture was used to transform into chemically competent 
DH5α E. coli cells using the transformation procedure described earlier, and the transformed 
cells were plated on LB-ampicillin agar plates and grown overnight at 37 °C. 
To screen the results of the ligation reactions, plasmid DNA from the resulting colonies 
was purified as described above and submitted to restriction enzyme digest using a restriction 
enzyme unique to the CYP26 insert but not present in the pKK233-2 plasmid itself. Following 
the restriction enzyme digestion, the DNA was analyzed by gel electrophoresis (0.8% agarose) to 
determine whether the DNA had been cut as a result of the digestion and thus contained the 
desired CYP26 DNA insert. Each gel also included a 1 kb DNA ladder as a size reference and a 
negative control (uncut plasmid). Plasmid DNA that tested positive for the CYP26 DNA insert 
was subsequently sent to Idaho State University to verify the faithful incorporation of all 
intended modifications and the absence of any undesired mutations using DNA sequencing of 
the complete gene.  
Segment Number of Cycles Temperature Time 
1 1 98°C 1 min 40 sec 
2 30 
98°C 10 sec 
Tm + 3°C 30 sec 
72°C 15 sec/kb 
3 1 Tm + 3°C 10 min 
Table 4-2: PCR thermal cycling parameters used to generate modified versions of human and mouse CYP26 
enzymes. 
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CYP26 Expression 
 Each of the CYP26 proteins of interest were expressed using the procedure described in 
Chapter 2: Methods, with certain modifications. As indicated by the data summarized in Tables 
4-3 and 4-4, these modifications included the use of the chaperone plasmid pGro7 and the 
incorporation of a stabilizing ligand during expression. The pGro7 plasmid encodes the protein 
folding chaperone team groES-groEL. Molecular chaperones such as groES and groEL are 
known to be involved in the protein folding process, and have been demonstrated to enhance 
bacterial expression of several mammalian P450 enzymes.26 Coexpression of CYP26 proteins 
with the groES-groEL chaperone team required the addition of L-arabinose and chloramphenicol 
for induction of expression and antibiotic selection of the pGro7 plasmid, respectively. In 
addition, all expressions utilizing the pGro7 chaperone plasmid, aside from the initial expression, 
were conducted over the course of two days rather than three to reduce cell death, which was 
indicated by the accumulation of a ring of cells along the wall of the flask. For expressions that 
utilized stabilizing ligands, a final concentration of 100-1000 times the published IC50 value was 
incorporated into the expression culture. These stabilizing ligands included the natural substrate 
retinoic acid (Sigma), the clinically-developed RAMBA liarozole (Tocris Bioscience), or an 
inhibitor of the recently published 3-(1H-imidazol- and triazol-1-yl) -2,2-dimethyl-3-[4-
(napthalen-2-ylamino)phenyl]propyl series of derivatives. The latter series of compounds, 
designated in these studies by ‘MCC’, was recently reported to inhibit CYP26A1 with low 
nanomolar potency in microsomal assays.19 
CYP26 Purification 
  Each of the CYP26 proteins of interest were initially purified using the cytochrome P450 
protein purification protocol described in Chapter 2: Methods. This standard protocol was further 
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optimized for selected CYP26 proteins to maximize protein yield. The greatest amount of 
optimization was conducted for human CYP26A1, as it represents the original protein of interest. 
As the poor stability and overall yield of purified human CYP26A1 became apparent, the cloning 
and purification of five other CYP26 proteins were pursued: human CYP26B1 and CYP26C1 
and mouse CYP26A1, CYP26B1, and CYP26C1. Based on total nanomoles of protein recovered 
following the first chromatographic step of the purification, optimization of mouse CYP26A1 
and mouse CYP26B1 were pursued as secondary targets of interest while further purification 
attempts of mouse CYP26C1, human CYP26C1, and human CYP26B1 were abandoned due to 
low protein yield.  
 Preparation of Microsomal Mouse CYP26A1 for Metabolism Studies 
 Mouse CYP26A1 was expressed for three days and harvested as described in Chapter 2: 
Methods. Following harvest, the cell pellet was re-suspended in 200 mL of 100 mM potassium 
phosphate, pH 7.4, containing 20% glycerol. Spheroplasts were then produced by treating the 
suspension for 30 min with 0.3 mg/mL lysozyme with stirring at 4 °C. Following lysozyme 
treatment, an equal volume of cold water was slowly added to the spheroplasts. After an 
additional incubation at 4 °C with stirring for 10 min, the spheroplasts were pelleted by 
centrifugation at 12,000 x g for 10 min at 4 °C. The spheroplasts were then lysed by freezing the 
pellet using either a liquid nitrogen bath or a dry ice/ethanol slurry. The frozen pellet was thawed 
and resuspended in 100 mL of 100 mM potassium phosphate, pH 7.4, containing 20% glycerol 
using manual homogenization on ice. To inhibit proteolysis, the cellular resuspension was 
supplemented with 0.5 µM PMSF and 10 µg/mL aprotinin. Following homogenization, the 
suspension was separated into approximately 50 mL aliquots and sonicated on ice using six 20 
sec pulses with 40 sec of cooling between pulses. The material was then centrifuged at 12,000 x 
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g for 10 min at 4 °C to remove cellular debris. Following this process, the supernatant was 
submitted to ultracentrifugation at 100,000 x g for 60 min at 4 °C. The final pellet was 
resuspended in 5 mL of retinoic acid metabolism assay buffer (100 mM potassium phosphate, 
pH 6.8, containing 20% glycerol) using manual homogenization on ice. The concentration of 
mouse CYP26A1 was analyzed by evaluating the reduced carbon monoxide difference spectrum 
and then aliquoted for metabolism assays with retinoic acid. 
 Assay to Detect Retinoic Acid Metabolism by Recombinantly Expressed CYP26 protein 
As the primary substrate of the CYP26 enzyme family, retinoic acid was the natural 
choice for metabolism assays designed to investigate the catalytic function of the CYP26 
proteins. Due to the limited success in generating large quantities of pure, stable P450 protein 
following NiNTA chromatography, metabolism assays were conducted with a microsomal 
preparation of CYP26A1 in addition to NiNTA-purified CYP26A1. Concentrations of 1 µM or 
10 µM RA were employed to evaluate the presence or absence of metabolic function for the 
various preparations of protein. CYP2E1 was employed as a positive reaction control because 
evidence in the literature indicated that it may be involved in modifications to in vivo retinoic 
acid levels in response to treatment with ethanol.27 A number of negative controls were also 
included to verify that any observed activity was specific to the presence of CYP26 enzyme and 
included samples that were 1) stopped with acetonitrile prior to initiation by the addition of 
NADPH, 2) not initiated by the addition of the obligatory electron donor NADPH, and 3) did not 
contain the obligatory redox partner protein cytochrome P450 reductase. 
Metabolism assays used a reconstituted system (RPS) consisting of 50 pmol of purified 
or microsomal CYP26A1 incubated with 200 pmol NADPH-cytochrome P450 reductase and 100 
pmol cytochrome b5 for 45 minutes on ice prior to use. RPS was added to 100 mM potassium 
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phosphate, pH 6.8, and 10 µM retinoic acid for a total volume of 250 µL. Samples were pre-
incubated at 37 °C for 3 minutes before initiating the reactions by the addition of 1 mM NADPH. 
Reactions were allowed to proceed for 30 minutes at 37 °C and were quenched with 250 µL 
acetonitrile and placed on ice. Samples were centrifuged at 4,500 x g for 6 minutes, and the 
amount of retinoic acid remaining was determined following HPLC separation. Separation of the 
reaction mixture was conducted by reverse phase HPLC with an isocratic mobile phase A of 
80% acetonitrile, 10 mM ammonium acetate, 1% acetic acid, and a flow rate of 1.6 mL/min held 
for 15 min. After each run, the column was washed with mobile phase B of 60% tert-butylmethyl 
ether and 40% methanol for 10 minutes at 1.6 mL/min, followed by re-equilibration in phase A. 
The elution of retinoic acid was monitored at 350 nm, and the identity of the peak was verified 
by comparison to the elution time of a standard of either 1 µM or 10 µM retinoic acid. The 
presence or absence in metabolic activity was determined based on comparison of the peak area 
to a retinoic acid standard in reaction buffer. 
Western Blotting 
 In preparation for SDS-PAGE, CYP26 protein samples were denatured by the addition of 
an equal volume of 2X SDS-PAGE loading dye (100 mM Tris-HCl, pH 6.8, 4% SDS, 0.2% 
bromophenol blue, 20% glycerol, 20 mM DTT) and heating at 100 °C for 3 minutes. Samples 
were then electrophoresed on 10% SDS-PAGE gels in reducing conditions. Protein was 
transferred to a polyvinylidene fluoride (PVDF) membrane by electrophoresis at 200 mV over 1 
hour at room temperature or overnight at 100 mA at 4 °C. Following transfer, the membrane was 
washed twice for 10 minutes with TBS buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.5) at room 
temperature and once for 10 minutes with TBS-TX buffer (20 mM Tris-HCl, 500 mM NaCl, 
0.05% Tween 20, 0.2% Triton X-100). Non-specific protein binding was blocked over the course 
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of a 1-hour incubation period conducted at room temperature with TBS buffer containing 3% 
bovine serum albumin. Excess bovine serum albumin was removed using two 10-minute washes 
with TBS-TX buffer and one 10-minute wash with TBS buffer at room temperature. Primary 
antibody (rabbit polyclonal IgG to human CYP26A1) was diluted into 3% bovine serum albumin 
in TBS at a 1:1,000 ratio and allowed to react for 1 hour at room temperature. The membrane 
was then washed twice for 10 minutes each with TBS-TX buffer and once for 10 minutes with 
TBS buffer at room temperature. A secondary antibody (anti-rabbit IgG) conjugated with 
alkaline phosphatase was diluted into 3% bovine serum albumin in TBS at a 1:2,000 ratio and 
allowed to react for 1 hour at room temperature. The membrane was then washed twice for 10 
minutes each with TBS-TX buffer and once for 10 minutes with TBS buffer at room 
temperature. The Western blot was developed with 5-bromo-4-chloro-3-indolyl phosphate/nitro 
blue tetrazolium (BCIP/NBT) developing solution until the signal was clearly visible. Upon 
reaching the desired endpoint, the reaction was stopped by rinsing with 1% acetic acid in water. 
Results 
Expression of CYP26 Proteins 
All attempts to express and purify human and mouse CYP26 proteins are summarized in 
Tables 4-3 and 4-4, respectively. A more visual representation of select data from these tables is 
also available in Figures 4.4 (human CYP26 expression and purification) and 4.5 (mouse CYP26 
expression and purification). Following either a two- or three-day expression period, a typical 
human CYP26A1 cell pellet exhibited medium-to-light brown coloration with a slightly darker 
brown top layer and a mass of approximately 25-30 grams per 2.25 L of expression culture 
(Table 4-3, Row A). This degree of coloration is notably lighter compared to what is observed 
following an expression of CYP2A enzymes in E. coli. Additionally, the cell mass was less than  
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Figure 4.4. Human cytochrome P450 26 protein expression (A) and purification (B). Protein yields reported 
as nanomoles of protein per liter of expression media and determined by reduced carbon monoxide difference 
following expression and NiNTA chromatography. Data not shown from expression trials F, G, I and 
purification trial A because reduced carbon monoxide difference spectrum was not collected or protein was not 
recovered. 
Protein: 
Trial:          A             B                C       D           E               H     J 
Ligand:                       ---            ---   ---      RA            RA         MCC 187       RA 
Detergent:               Cymal-5    Cymal-5     Tergitol + sodium cholate ------------------>    Cymal-5 
Protein: 
Trial:  B           C            D            E            F            G           H             I             J 
Ligand:               ---          ---          RA         RA        RA         RA     MCC 187    ---         RA 
Detergent:       Cymal-5  Tergitol + sodium cholate ----------------------------->  Cymal-5 ------> 
A 
B 
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Figure 4.5. Mouse cytochrome P450 26 protein expression (A) and purification (B). Protein yields reported 
as nanomoles of protein per liter of expression media and determined by reduced carbon monoxide difference 
following expression and NiNTA chromatography. Data not shown from expression trial I and purification trial 
C because reduced carbon monoxide difference spectrum were not collected. 
A 
B 
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what is typically observed for the expression of CYP2A enzymes (approximately 35-40 grams) 
under identical expression conditions. Both qualities suggest that the expression of human 
CYP26A1 was lacking in comparison to the normal, healthy expression of P450 protein. 
A number of variables were therefore addressed to promote a higher level of expression, 
including coexpression with the chaperone plasmid pGro7 (Takara Bio Inc., Mountain View, 
CA) (Table 4-3, Rows B-G), a reduced expression period of two days versus three, and addition 
of the natural substrate retinoic acid (Table 4-3, Rows D-G) or an inhibitor of the ‘MCC’ series 
(Table 4-3, Row H). The pGro7 plasmid encodes genes for the groES-groEL protein folding 
chaperone team, which is designed to facilitate the protein folding process over the course of 
expression. A reduction in the expression period by a day was intended to reduce cell 
accumulation along the wall of the flask during expression, which may be an indicator of cell 
death. Finally, the introduction of a ligand such as the natural substrate or an inhibitor may 
promote higher levels of protein expression by facilitating the stabilization of the protein as it is 
generated. The only expression that suggested moderate improvement, based on protein yield 
using reduced carbon monoxide difference spectral determination prior to NiNTA 
chromatography and slightly darker coloration of the cell pellet, was the result of the addition of 
the inhibitor MCC 187 (Table 4-3, Row H). Whether the improvement was due to the use of an 
optimized detergent system, the presence of an optimized stabilizing ligand in the protein 
expression and protein extraction steps, or a combination of the three cannot be established, but 
overall, the use of the pGro7 chaperone plasmid tended to suggest either negative or no effect on 
the amount of CYP26 enzyme expressed. This is based on the fact that the major difference 
between expressions in TOPP3 cells (Table 4-3, Rows A,H) and TOPP3 pGro7 cells (Table 4-3, 
Rows B-G) was that the former tended to yield more protein following extraction, with no 
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significant difference in cell pellet mass or coloration between the two. As a result, expressions 
of the five additional CYP26 proteins exclusively utilized the TOPP3 E. coli cell line without the 
pGro7 chaperone plasmid. 
With the limited progress demonstrated by optimization to the expression of human 
CYP26A1, the remaining five CYP26 proteins in human and mouse were similarly pursued in 
hopes of greater success. Of the five remaining CYP26 proteins, mouse CYP26A1 (Table 4-4, 
Row A) and mouse CYP26B1 (Table 4-4, Row E) demonstrated the greatest prospect for 
expression and purification based on total nanomoles of protein determined to be present prior to 
the first chromatographic step (pre-NiNTA) as measured by the reduced carbon monoxide 
difference spectrum. The typical cell pellet following a three-day expression of mouse CYP26A1 
or CYP26B1 was similar to that of human CYP26A1, with a slightly darker top layer, deeper 
brown coloration throughout, and an average cell mass of 30 grams per 2.25 L of expression 
culture, with a couple expressions of mouse CYP26B1 exceeding 35 grams. 
Subsequent efforts to optimize the generation of the five remaining CYP26 proteins, 
including mouse CYP26A1 and CYP26B1, were focused on facilitating protein stabilization. To 
accomplish this, a variety of tight-binding ligands, including both substrate and inhibitors, were 
introduced into the cell culture media during expression and/or to the purification buffer during 
membrane extraction. The additional presence of liarozole during the extraction of mouse 
CYP26A1 from the E. coli membrane resulted in a dramatic decrease in protein recovery from 
218 nmol P420 (Table 4-4, Row B) to 87 nmol (Table 4-4, Row C), though a small proportion of 
P450 was recovered at this stage for the first time. Substitution of liarozole by the more potent 
inhibitor MCC 154 during both expression and membrane extraction resulted in a slight 
improvement in overall yield compared to the use of liarozole with a total of 138 nmol recovered 
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following membrane extraction (Table 4-4, Row D), though only 2 nmol was attributed to P450 
protein with a maximum wavelength of absorbance at 450 nm in the reduced carbon monoxide 
difference spectrum. The substrate RA was used from the very first expression of mouse 
CYP26B1 to facilitate protein stabilization, which generally resulted in yields of 234-420 nmol 
(Table 4-4, Rows E-F) following membrane extraction. Substitution of RA with the potent 
inhibitor MCC 154 during expression and membrane extraction resulted in a decrease in overall 
yield to 142 nmol (Table 4-4, Row H), with the appearance of a very small population of P450. 
Altogether, quantitative measures of total protein recovered following membrane extraction and 
qualitative measures of cell pellet mass and coloration suggested that the introduction of tight 
binding ligands failed to make any significant degree of improvement on the expression of either 
mouse CYP26A1 or CYP26B1. 
 Human CYP26B1, human CYP26C1, and mouse CYP26C1 were only expressed a single 
time each and were not pursued for further optimization. Unlike the dark coloration exhibited by 
the mouse CYP26A1 and CYP26B1 E. coli cell pellets, the human CYP26B1 cell pellet 
harvested after three days of expression was much lighter brown in color with a rosy tint (Figure 
4.6) and a similarly red-brown top layer that was very thin. Both qualities are in direct opposition 
with the deep brown coloration and dark, thick top layer attributed to TOPP3 cells expressing 
other P450 enzymes in appreciable yields, although the cell mass was very comparable to any of 
the other five CYP26 proteins investigated at 33 grams. The human CYP26C1 pellet was not 
quite as poor as human CYP26B1, and exhibited a normal brown tone, a very thin, dark top 
layer, and a cell mass just below average at 28 grams. Qualitatively, visual inspection of the 
mouse CYP26C1 E. coli cell pellet suggested that this protein was expressed in high levels based 
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on the deep brown color and dark top layer exhibiting the same thickness seen with mouse 
CYP26A1 and mouse CYP26B1. 
Purification of CYP26 proteins 
 A total of eight attempts were made to optimize the purification of human CYP26A1 to 
generate enough pure protein for characterization studies. The initial two purifications of human 
CYP26A1 utilized the detergent Cymal-5, as this detergent has proven effective in solubilizing 
multiple truncated mammalian P450 enzymes studied in the lab, including CYP2A6 and 
CYP2A13. The first purification with Cymal-5 failed in the sense that no protein was 
successfully recovered from the elution fractions of the NiNTA column (Table 4-4, Row A). 
This was because the protein washed off the column with the use of the 8 mM histidine buffer, 
which serves to remove impurities that have only a weak affinity for the NiNTA column. To 
prevent this loss, the use of two column-volumes of 8 mM histidine was replaced with four 
column-volumes of loading buffer. The elimination of the 8 mM histidine buffer proved to be 
effective in that subsequently little P450 protein appeared to be lost at the wash step of the 
NiNTA column (Table 4-4, Row B). Unfortunately, a total of only 11 nmol of P420 were 
recovered in the elution fractions. As a result, subsequent purifications used an optimized 
Figure 4.6.  Representative cell 
pellet samples of CYP26-
expressing TOPP3 E. coli cells. 
The human CYP26B1 cell pellet 
(left) harvested after three days of 
expression is light brown in color 
with a rosy tint. This quality of 
coloration is quite different than 
the dark brown coloration 
exhibited by mouse CYP26A1 
(right) and mouse CYP26B1 (not 
shown). The darker brown cell 
pellet is more consistent with the 
higher levels of cytochrome P450 
expression such as observed with 
human CYP2A expressing cells. 
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detergent system of sodium cholate and Tergitol (1% each) (Table 4-4, Rows C-H), a 
combination which had been reported in the literature to work effectively for the purification of 
CYP26 protein expressed in insect cells. The combination of these two detergents appeared to be 
beneficial based on the detection of a small amount of P450 protein following extraction and 
ultracentrifugation, where only P420 had been present in purifications utilizing Cymal-5. 
Unfortunately, this same degree of improvement was not evident in the quality or yield of protein 
following NiNTA column chromatography. Where 11 nmol P420 was recovered following 
NiNTA chromatography with Cymal-5 (Table 4-3, Row B), 15 nmol of P420 was recovered at 
the same stage with the combination of sodium cholate and Tergitol (Table 4-3, Row C). Further 
optimization to the purification of human CYP26A1 involved the inclusion of substrate (Table 4-
3, Rows D-G) or inhibitor (Table 4-3, Row H) to stabilize the protein over the course of 
purification as well as an increased concentration of NaCl from 0.1 M to 0.2 M (Table 4-3, Rows 
E-G) to decrease cloudiness of the protein solution upon elution. The latter was perceived to be 
the result of protein precipitation, which has been successfully controlled in the purification of 
other truncated mammalian P450 enzymes by increasing the ionic strength of the buffer. When 
an increase in the salt content of the elution buffer failed to completely prevent protein 
precipitation, measures were taken to further dilute the protein with buffer as it eluted off the 
column (Table 4-3, Row G). The combination of these approaches failed to significantly increase 
the yield of human CYP26A1 protein following NiNTA chromatography, so the purification of 
five additional CYP26 proteins where therefore pursued. 
Following multiple failed attempts to optimize the purification of human CYP26A1, each 
of the five remaining CYP26 proteins were purified once using the standard purification protocol 
described in Chapter 2: Methods. The results of these five initial purifications were used to 
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determine which protein(s) represented the most potential for success in purification using a 
comparison of the total yield of protein recovered following NiNTA column chromatography 
(post-NiNTA) and the color of the protein solution over the course of protein extraction and 
purification. A dark red color serves as a visual indication of a high content of heme-containing 
protein in solution, with lighter red indicating lesser concentrations and a lack of red altogether 
indicating the presence of little or no heme-containing protein. With as much as 40-50 nmol of 
protein recovered from the NiNTA column, mouse CYP26A1 and mouse CYP26B1 were 
selected for further purification optimization over the lesser yielding proteins mouse CYP26C1, 
human CYP26B1, and human CYP26C1. 
A total of four attempts were made to optimize the purification of mouse CYP26B1. The 
first purification of mouse CYP26B1 resulted in a loss of half of the P450 protein at the wash 
step with 8 mM histidine buffer, and a recovery of only 50 nmol protein upon elution (Table 4-4, 
Row E). Because elimination of the wash buffer altogether results in a significant reduction in 
the final purity of the protein, a wash buffer containing 100 mM glycine rather than histidine was 
utilized in the second purification of mouse CYP26B1. Glycine has a single nitrogen donor atom 
and can poorly compete for Ni2+ binding, and thus should serve as a less stringent option for 
removing impurities. The reality is that more P450 protein was lost at the wash step with the 
glycine wash than with the histidine wash, with the 24 nmol of protein recovered following 
NiNTA chromatography originating from the wash fractions (Table 4-4, Row F). Subsequent 
purifications replaced the application of two column-volumes of wash buffer with four column-
volumes of loading buffer (Table 4-3, Rows G-H). This reduced the loss of P450 during the wash 
step, but overall had little effect on the final yield of protein following NiNTA chromatography. 
As with human CYP26A1, alternative detergents and tight-binding ligands were investigated in 
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hopes of providing improved protein stabilization and higher yield. The combined use of Cymal-
5 and RA for the purification of mouse CYP26B1 allowed for the recovery of 24-50 nmol P420 
(Table 4-4, Rows E-F), whereas the combination of the optimized detergent system sodium 
cholate and Tergitol and the potent inhibitor MCC 154 allowed for the recovery of only 13 nmol 
P420 (Table 4-4, Row H). The use of Emulgen-913 in the absence of stabilizing ligand allowed 
for the recovery of 32 nmol P420 following NiNTA chromatography (Table 4-4, Row G), which 
is less than the 50 nmol of P420 recovered from the first purification of mouse CYP26B1 with 
Cymal-5 in the presence of RA (Table 4-4, Row E) but greater than the 13 nmol recovered from 
the purification of mouse CYP26B1 using sodium cholate and tergitol in the presence of MCC 
154 (Table 4-4, Row H). Altogether, the use of alternative detergents and tight-binding ligands 
failed to promote a significant improvement in the yield of mouse CYP26B1 following NiNTA 
chromatography. 
 With the results of the initial purification of mouse CYP26A1 (Table 4-4, Row A) 
indicating similar promise as mouse CYP26B1 (Table 4-4, Row E), optimization to the 
purification of mouse CYP26A1 was pursued over the course of three additional purifications. 
Unlike human CYP26A1, the fractions did not exhibit any cloudiness upon elution from the 
NiNTA column that would suggest precipitation, so no attempts were made to alter the 
concentration of NaCl in the elution buffer or to otherwise alter the protein upon elution. As a 
result, the only modifications made to the purification process were the choice of detergent and 
stabilizing ligand, since the 8 mM histidine buffer was eliminated from the very first purification 
(Table 4-4, Row A). Once again, the combination of sodium cholate and Tergitol appeared to 
make a small improvement by promoting the appearance of a small amount of P450 protein upon 
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NiNTA elution (Table 4-4, Rows B, D), wereas only P420 had been present previously. 
However, the addition of stabilizing ligands failed to similarly promote the 
proportion of P450 over P420 or to increase the quantity of protein recovered in the NiNTA 
elution fractions. The use of the inhibitor MCC 154 in combination with the detergents sodium 
cholate and Tergitol resulted in the recovery of 16 nmol P420 and 7 nmol P450 (Table 4-4, Row 
D) compared to the 17 nmol P420 and 2 nmol P450 recovered following NiNTA 
chromatography in the absence of stabilizing ligand using the same combination of detergents 
(Table 4-4, Row B). A final attempt was made to perform a scale-up of the purification in the 
absence of ligand by starting with a 60 gram cell pellet, but the amount of protein recovered 
following NiNTA chromatography (Table 4-4, Row B) was less than or equal to the purification 
smaller mouse CYP26A1-expressed E. coli cell pellets (Table 4-4, Rows A, D).  
Characterization of Human and Mouse CYP26A1 by Western blot and Reduced Carbon 
Monoxide Difference 
Reduced carbon monoxide difference (CO-difference) spectra served as the primary 
means of monitoring the presence and quality of CYP26 protein over the course of each 
purification that was performed. As a whole, the CO-difference spectra indicated that the CYP26 
proteins were poor in quality due to the predominance of a peak at 420 nm rather than at 450 nm, 
which was often either absent or much less pronounced. Representative CO-difference spectra 
for human CYP26A1 and mouse CYP26A1 are shown in Figure 4.7. The CO-difference spectra 
of both CYP26 proteins illustrate the presence of a larger proportion of P420 compared to P450 
prior to (post-ult) and following NiNTA chromatography (NiNTA elution).  
Western blot analysis was used as a secondary method for the detection of CYP26 protein 
over the course of purification. Protein was sampled prior to NiNTA chromatography (post-ult), 
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as well as at the loading, wash, and elution stages of NiNTA chromatography. Initially, an anti-
His antibody was utilized for the detection of CYP26 protein by means of the 4X-histidine tag 
engineered into each of the six modified CYP26 proteins. Unfortunately, no band at ~53 kDa 
band (expected molecular weight) was detected within CYP26-containing samples using the 
anti-His antibody, so a more specific polyclonal antibody of human CYP26A1 was purchased. 
Though this new antibody was unable to detect CYP26B1 or CYP26C1, it allowed for the 
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Fig 4.7. Reduced carbon monoxide difference spectra of CYP26A1. Reduced carbon monoxide difference (CO-
difference) spectra were used to quantify the amount of active (P450) and inactive (P420) protein in preparations of 
human CYP26A1 (A,B) and mouse CYP26A1 (C,D) prior to (post-ult) and following NiNTA chromatography 
(NiNTA elution). The reduced carbon monoxide difference spectra of human CYP26A1 and mouse CYP26A1 
indicate the presence of a larger proportion of P420 compared to P450 in all samples analyzed, as well as a 
significant loss of protein following NiNTA chromatography.  
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successful detection of both human and mouse CYP26A1 with a band near 50 kDa in NiNTA 
elution fractions, and a faint band at the same molecular weight from protein sampled prior to 
NiNTA chromatography (Figure 4.8). 
Functional Characterization of Mouse CYP26A1 using Retinoic Acid Metabolism 
 The CYP26 protein generated over the course of expression and purification studies was 
further characterized by its ability to metabolize the substrate retinoic acid (RA) over the course 
of three separate trials. Mouse CYP26A1 was selected for these studies over the other five 
CYP26 proteins based on the fact that 1) CYP26A1 is reported to be the most dedicated to 
A 
B 
C 
Fig 4.8. Detection of CYP26A1 by Western blot. Human CYP26A1 (A) and mouse CYP26A1 (B) protein 
sampled following ultracentrifugation (post-ult) and at the loading, wash, and elution stages of NiNTA 
chromatography were each analyzed using Western blot analysis with human CYP26A1 polyclonal antibody 
(AbCam). Protein bands near ~50 kDa were detected in both human and mouse protein samples collected 
following ultracentrifugation (post-ult) and following NiNTA chromatography (elution). The absence of a protein 
band near ~50 kDa in the NiNTA wash samples suggests that CYP26 protein (both human and mouse) was not lost 
during this stage of NiNTA chromatography, although a faint band present in the human CYP26A1 loading sample 
suggests that some CYP26 protein was lost during the loading stage. 
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retinoic acid metabolism within the CYP26 family and 2) mouse CYP26A1 could be generated 
in greater quantities with a larger proportion of P450:P420 compared to the human form. Two 
alternative preparations of mouse CYP26A1 were selected these assays. One was a microsomal 
preparation of E. coli cells expressing mouse CYP26A1. The second was mouse CYP26A1 
purified using NiNTA chromatography. Prior to retinoic acid metabolism, the total content of 
P420 and P450 within each of the protein preparations was determined by the reduced carbon 
monoxide difference spectrum. While the microsomal preparation consisted entirely of P420 
protein at a concentration of 20.0 µM, the NiNTA-purified protein consisted of a small amount 
of P450 at a concentration of 0.8 µM in addition to a larger population of P420 at a concentration 
of 3.3 µM. 
The combined results of all three trials failed to indicate any metabolic activity for mouse 
CYP26A1 in the presence of the substrate RA (Figure 4.9). Comparison of the microsomal and 
purified mouse CYP26A1 reaction samples to a standard containing 1 µM RA in the first of 
three trials (Figure 4.9 A) appeared to indicate no consumption of RA within the purified protein 
sample reactions, although a small degree of variation between the standard and the microsomal 
protein preparation encouraged further investigation. As a result, a second trial was performed to 
further assay the function of microsomal mouse CYP26A1 with the following modifications: 1) 
an increased substrate concentration of 10 µM RA, 2) additional negative control reactions (no 
reaction, no NADPH, no P450 reductase), and 3) parallel assays to investigate the prospective 
utility of CYP2E1 as a positive control. The results of this second trial (Figure 4.9 B) further 
provided evidence of the inability of mouse CYP26A1 protein to metabolize RA, but the 
suggestion of a very slight reduction in RA peak area in the CYP2E1 reaction samples gave  
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Figure 4.9 Characterization of recombinant 
CYP26 protein by RA metabolism. The 
metabolic function of mouse CYP26A1 and 
human CYP2E1 were evaluated based on the 
ability to metabolize the substrate RA over the 
course of three separate trials (A, B, and C). In 
sample reactions containing concentrations of 1 
µM RA (A) or 10 µM RA (B, C), metabolic 
activity was assessed based on comparison of 
the RA peak area to an RA standard and 
various control reactions. A lack of reduction in 
the RA peak area signified an inability of either 
CYP26A1 or CYP2E1 to metabolize the 
substrate RA. 
A 
B 
C 
 76 
reason to further investigate CYP2E1-mediated RA catabolism in a third and final trial. The 
results of the third trial (Figure 4.9 C) served as final verification of CYP2E1’s inability to 
metabolize RA based on the lack of a significant reduction in the RA peak area upon comparison 
to all relevant controls. 
Discussion 
The development of truly selective CYP26 inhibitors and improved RAMBAs would be 
greatly facilitated by more detailed structural and functional characterization of the CYP26 
family of enzymes. Very little is known about the structures, metabolic pathways, or kinetics of 
the CYP26 enzymes aside from the fact that they serve a dominant role in the catabolism of RA 
through atRA hydroxylation. The present study involved the development of a new method for 
the expression and purification of CYP26 proteins with yield and purity that exceeded published 
methods of CYP26 protein production, which involve either expression in transfected 
mammalian cells or baculovirus infected insect cells.6,7,10,20,22,28,29 This study represents the first 
account of recombinant CYP26 protein expression in E. coli resulting in any amount of active 
P450 protein, as evaluated by the reduced carbon monoxide difference spectrum. The only other 
published attempt to express CYP26A1 in E. coli was a reported failure based on the fact that 
only P420 was detected by the reduced carbon monoxide difference spectrum.30  
These studies specifically addressed the initial prerequisite of providing the capacity for 
generating large quantities of CYP26 enzyme by employing E. coli as an expression host. The 
additional challenges that come with studying a membrane-bound protein were subsequently 
addressed by modifying the CYP26 proteins for enhanced expression and ease of purification. 
Specifically, common molecular biology techniques were used to remove the N-terminal 
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transmembrane sequence, incorporate a short hydrophilic sequence, and add four histidine 
residues to the C-terminus of each of the six CYP26 proteins used in these studies.  
The real challenge within the project arose during optimization studies designed to 
enhance the yield and quality of CYP26 during expression and purification. A number of 
variables were assessed to specifically address both of these qualities, including use of the 
chaperone plasmid pGro7 and the most effective detergents and stabilizing ligands based on 
available reports. The detergents employed include Cymal-5, a detergent successfully employed 
for the purification of the CYP2A family of proteins,24,25 and the combination of sodium cholate 
and Tergitol, which has been published as an effective detergent system for the purification of 
full-length CYP26 expressed in insect cells.6,7,31 The ligands used to promote protein 
stabilization include the native substrate retinoic acid, the clinically-developed RAMBA 
liarozole, and two compounds from a recently published series of low nanomolar inhibitors 
referred to as ‘MCC’ inhibitors.19 Unfortunately, a combination of even the best available 
detergents and stabilizing ligands demonstrated limited effectiveness in generating P450 in 
higher quality or enhanced yield. The most optimized purifications of the CYP26 proteins 
exhibiting the best expression did not exceed yields of 50 nmol of total protein following a single 
chromatographic step, with the majority of that protein indicating a lack of activity according to 
assessment by the reduced carbon monoxide difference spectrum. This lack of activity appeared 
to be confirmed when two different preparations of CYP26A1 failed to metabolize the substrate 
retinoic acid. 
Despite the limited success in the studies summarized here, these results serve as a 
critical foundation for future work for the optimization of CYP26 expression and purification. 
The range of possibilities that could lead to the successful generation of this family of proteins 
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has by no means been exhausted. For the sake of time, the CYP26 proteins were expressed 
within these studies in a single E. coli cell line (with or without the use of a plasmid chaperone), 
and optimization was focused on using the best stabilizing ligands and detergents available. 
Many other available E. coli cell lines remain to be tested, as well as a great variety of 
detergents. Another possibility may be that the CYP26 proteins require alternative modifications 
to the amino acid sequence. Since all previous studies have been conducted with full-length 
CYP26 protein, it is possible that the modifications to the structure employed in these studies 
may have disrupted the native stability of CY26 to a point that could not be rescued with any 
combination of detergents and stabilizing ligands. Finally, new technology in the expression and 
purification of recombinant P450 proteins may offer additional insights into the successful 
generation of particularly challenging proteins, such as the CYP26 proteins. 
Conclusion 
Although the CYP26 enzymes are known to be important mediators of RA catabolism in 
the body, the ability to generate detailed structural and functional data on this family of enzymes 
has been hindered by the inability to generate sufficient amounts of recombinant enzyme 
necessary for these studies. To address this problem, expression and purification studies were 
pursued for all three members of the CYP26 family (CYP26A1, CYP26B1, CYP26C1) from 
both mouse and human with the immediate goal of generating CYP26 protein with enhanced 
yield and purity. The results of these studies serve as the first and only known record of the 
recombinant expression of CYP26A1 and CYP26B1 in E. coli leading to any amount of active 
P450 protein by the reduced carbon monoxide difference spectrum. Of the six CYP26 enzymes 
expressed, mouse CYP26A1 and mouse CYP26B1 demonstrated the highest expression levels 
based on 1) total nanomoles of protein determined using reduced carbon monoxide difference 
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spectral determination prior to the first chromatographic step and 2) the quality of the TOPP3 E. 
coli cell pellet harvested after three days of CYP26 protein expression. As a result, these two 
proteins, in addition to the original target of interest human CYP26A1, were selected for 
additional studies with the purpose of increasing the yield and quality of protein generated from 
the initial expressions and purifications. A number of variables were addressed over the course 
of these optimization studies. During expression of CYP26, protein stability was addressed 
through the use of the protein folding chaperone pGro7 and various stabilizing ligands including 
the natural substrate retinoic acid, the clinically-developed retinoic acid metabolism blocking 
agent liarozole, and two inhibitors of a recently published 3-(1H-imidazol- and triazol-1-yl) -2,2-
dimethyl-3-[4-(napthalen-2-ylamino)phenyl]propyl series of derivatives designated as ‘MCC’ 
inhibitors.19 During purification of CYP26, the wash buffer was modified to reduce P450 loss 
prior to elution, stabilizing ligands continued to be employed, and several detergents were 
sampled. Of the changes that were made, the use of the detergents sodium cholate and tergitol 
and the incorporation of the ‘MCC’ inhibitors appeared to have the greatest benefit to the 
expression and purification of CYP26 protein. By incorporating both of these modifications, 
CYP26 protein could be generated in yields of 300-400 nmol per 2.25 L expression with the 
ability to recover 5-50 nmol following NiNTA chromatography. However, reduced carbon 
monoxide difference assays conducted prior to and following NiNTA chromatography indicated 
that the quality of CYP26 protein was poor based on the predominance of an absorbance peak at 
420 nm compared to absorbance at 450 nm. When functional assays of RA metabolism were 
conducted with mouse CYP26A1 protein, no significant difference in the substrate RA was 
observed compared to control reactions. As a result, further optimization will be required to 
 80 
reach the original goal set forth to generate pure recombinant CYP26 enzymes for basic kinetic 
and structural determination studies. 
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Chapter 5 
 
Conclusions 
 
The goal of this thesis research was to contribute to an understanding of how substrates 
and inhibitors interact with individual P450 enzymes so that it may be applied to the prediction 
of chemical toxicology and the development of enhanced chemotherapeutic agents. Two 
different families of P450 enzymes have been examined to better understand the biochemical 
properties that serve as the foundation for methods of selectively targeting P450 enzymes. The 
first is the xenobiotic metabolizing CYP2A family, which is involved in the activation of several 
procarcinogens, including the tobacco-related nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone (NNK). The second is the CYP26 family, which is involved in the metabolism of 
retinoic acid (RA), the endogenous derivative of vitamin A. 
The human CYP2A family consists of the functional enzymes CYP2A6 and CYP2A13 
which share an amino acid sequence identity of 94%.1 While CYP2A6 is mainly expressed in the 
liver and CYP2A13 is primarily expressed in the respiratory tract,2 both enzymes have many 
small, cyclic substrates in common, including nicotine,3 para-nitrophenol,4 coumarin,2 and the 
nicotine-derived compound cotinine.3 In addition, CYP2A13 preferentially metabolizes or has 
the sole ability to activate a number of procarcinogenic compounds, including aflatoxin B1,5 4-
aminobiphenyl,6 and the tobacco-related nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK).2,7 Each of these compounds requires activation to generate reactive 
intermediates that ultimately result in carcinogenicity. To evaluate the involvement of CYP2A6 
versus CYP2A13 in the metabolism and activation of potentially harmful chemical agents in 
vivo, selective inhibitors are needed. Several compounds were reported in the literature to 
selectively inhibit CYP2A6 before CYP2A13 enzyme activity was recognized. These include: 
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phenethyl isothiocyante (PEITC),8 4-dimethylaminobenzaldehyde (DMABA),9 8-
methoxypsoralen (8-MOP),10 tranylcypromine,11 tryptamine,11 pilocarpine, (S)-nicotine,12 (R)-
(+)-menthofuran,13 and β-nicotyrine12. The goal of this project was to determine which of these 
inhibitors are actually able to discriminate between CYP2A6 and CYP2A13. The ability of these 
inhibitors to discriminate between CYP2A6 and CYP2A13 activity was evaluated using parallel 
assays for the inhibition of para-nitrophenol (pNP) 2-hydroxylation using recombinant, purified 
CYP2A protein. The results of these studies suggests that only (R)-(+)-menthofuran and 
tranylcypromine demonstrate even a 10-fold preference for CYP2A6 inhibition over CYP2A13, 
and that only 8-MOP has a >5-fold selectivity for CYP2A13 over CYP2A6. Tryptamine and 
DMABA were determined to be only moderately (5- to 10-fold) selective for CYP2A6 
inhibition, while the remaining compounds (S)-nicotine, PEITC, β-nicotyrine, and pilocarpine 
demonstrated relatively little preference for either CYP2A6 or CYP2A13. The results of these 
studies serve as the first explicit determination of the selectivity of these compounds for enzymes 
within the CYP2A family and can be used as a guide for the selection of CYP2A-selective 
inhibitors in studies that seek to accurately distinguish between CYP2A6 and CYP2A13 in the 
metabolism or activation of xenobiotic compounds. 
Possible future directions for this project may include the use of docking studies to 
evaluate the binding interactions that serve as an underlying basis for the moderate, observed 
CYP2A selectivity. Docking studies conducted with the published crystal structures of CYP2A6 
and CYP2A13 with all nine inhibitors might provide insight into the interactions governing the 
binding of the most selective CYP2A6 inhibitors tranylcypromine and (R)-menthofuran as 
opposed to relatively non-selective inhibitors such as (S)-nicotine and β-nicotyrine. Such 
information could be useful in the rational development of more selective CYP2A inhibitors by 
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taking maximal advantage of the proposed binding interactions that appear to confer the greatest 
selectivity between CYP2A6 and CYP2A13. Another possible means of evaluating the 
biochemical interactions that allow these inhibitors to discriminate between CYP2A6 and 
CYP2A13 activity is the use of functional assays conducted with CYP2A6 mutants. Four amino 
acids located within the CYP2A active site have been identified by the Scott lab to play key roles 
in the differing the abilities of CYP2A6 versus CYP2A13 enzymes to metabolize the substrate 
phenacetin.14 The inhibition assays employed in the completed studies of wild-type CYP2A 
enzymes can be extended to include CYP2A6 mutants containing one or more of these residue 
changes to evaluate the importance of these individual active site residues to the selectivity of the 
inhibitors characterized thus far. 
The CYP26 family of enzymes are important mediators of the in vivo catabolism of the 
endogenous derivative of vitamin A, retinoic acid (RA), and serve as therapeutic targets for the 
prevention of RA resistance. Geometric isomers of RA such as all-trans-RA (atRA) and 13-cis-
RA have been found useful in cancer therapy and the treatment of dermatological conditions, but 
resistance to RA-based therapies is often experienced in patients undergoing prolonged treatment 
as a result of increased plasma clearance. The development of selective and potent CYP26 
inhibitors has been restricted due to the limited structural and functional data available for this 
family of enzymes. Present limitations in CYP26 research are due, in large part, to that fact that 
the majority of CYP26 research published to date has relied on assays performed with 
transfected cells, microsomal fractions prepared from tissue samples, or microsomal fractions 
prepared from cultured cells.15-19 These studies provide only limited structural and functional 
data based on the scarce quantities and low purity of these types of enzyme preparations. As a 
result, the immediate goal of this second project was to produce pure, recombinant, functional 
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CYP26 enzyme in yields that exceeded those attainable by methods currently available in the 
literature. The production of purified CYP26 enzymes was based on the combination of proven 
methods for the expression and purification of other truncated, mammalian P450 enzymes and 
the use of detergents and stabilizing ligands specific for the CYP26 enzymes. The combination 
of these approaches led to the expression of mouse CYP26A1 and CYP26B1 proteins in yields 
of 200-400 nmol per 2.25 L of E. coli expression media and the ability to recover 20-50 nmol 
following a single chromatographic step using immobilized metal affinity chromatography. 
However, reduced carbon monoxide difference spectra collected prior to and following column 
chromatography indicated that the majority of this protein was inactive based on the 
predominance of an absorbance peak at 420 nm, though a small amount of P450 was also 
detected. Additionally, neither purified nor microsomal preparations of mouse CYP26A1 showed 
any indication of metabolic activity in the presence of the natural substrate RA. Regardless, the 
results of these studies serve as the first and only known record to date of recombinant 
expression of human or mouse CYP26 enzymes in E. coli resulting in any amount of active P450 
protein as evaluated by the reduced carbon monoxide difference spectrum. Still, further 
optimization will be required to reach the original goal set forth of generating pure, recombinant, 
functional CYP26 enzymes for basic kinetic and structural determination studies. 
Within the last two years, more than one research group has published data on binding 
and metabolism of known CYP26 substrates and inhibitors using proteins expressed 
recombinantly in baculovirus infected insect cells.17,20,21 Though expression in insect cells has 
thus been demonstrated to be sufficient to conduct functional characterization studies, structural 
determination by X-ray crystallography requires a more robust expression system. As a result, 
future work in this project would involve optimizing the method of CYP26 expression in E. coli 
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that has been described so far. Since the CYP26 enzymes expressed using this host were 
inactive, future efforts should focus on promoting the functional integrity of the CYP26 enzymes 
upon expression. One potential approach to accomplishing this would be to explore alternate 
modifications to the N-terminal sequence. Though the truncation used in these studies was based 
on the successful truncation of other mammalian P450 proteins, it is possible that the integrity of 
the CYP26 tertiary structure is more sensitive to the removal of this region. Based on hydropathy 
plot analysis, a lesser truncation involving the removal of the first 24 amino acid residues 
(compared to 42) would still be sufficient in removing the N-terminal transmembrane helix while 
keeping more of the wild-type protein intact. In addition to a smaller N-terminal truncation, 
different E. coli cell lines and plasmids could be employed. Both of these components can have a 
significant effect on the success or failure of the recombinant expression of other mammalian 
P450 enzymes in E. coli. 
The research projects described within this thesis represent critical stepping stones in the 
process of understanding how substrates and inhibitors interact with individual P450 enzymes. A 
thorough kinetic evaluation for the ability of known CYP2A inhibitors to discriminate between 
CYP2A6 and CYP2A13 is directly applicable to predicting and/or evaluating the chemical 
toxicology of xenobiotic compounds that serve as CYP2A substrates, including procarcinogens 
that become activated upon CYP2A-mediated metabolism. An enhanced method for generating 
large amounts of pure, recombinant CYP26 enzyme would enable basic structural and kinetic 
studies to facilitate the development of enhanced retinoic acid metabolism blocking agents for 
the treatment of cancer. Altogether, the studies of these two very different families of P450 
enzymes serve to facilitate the selective targeting of P450 enzymes. Selective inhibition of the 
CYP2A enzymes provides a means of protection against harmful chemical species, while 
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selective inhibition of the CYP26 enzymes is important for the development of enhanced 
chemotherapeutic agents. 
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